

Objection Deadline: August 25, 2020 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , ¹	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**TENTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD JUNE 1, 2020 THROUGH JUNE 30, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	June 1, 2020	June 30, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$870,154.80 (80% of \$1,087,693.50)	
Total expenses requested in this statement:	\$193.79	
Total fees and expenses requested in this statement:	\$870,348.59	
This is a(n): <u> X </u> Monthly Application <u> </u> Interim Application <u> </u> Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD JUNE 1, 2020 THROUGH JUNE 30, 2020**

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	18.3	\$ 21,868.50
Richard Collura	Managing Director	\$1,090	49.3	53,737.00
Jesse DelConte	Director	\$950	173.7	165,015.00
Kevin M McCafferty	Director	\$950	163.4	155,230.00
Mark F Rule	Director	\$910	42.9	39,039.00
Michael Hartley	Director	\$840	3.7	3,108.00
Gabe J Koch	Director	\$840	163.2	137,088.00
HS Bhattal	Director	\$840	24.1	20,244.00
Elizabeth S Kardos	Director	\$710	12.9	9,159.00
Ryan D Sublett	Senior Vice President	\$735	56.0	41,160.00
Isabel Arana de Uriate	Senior Vice President	\$690	19.3	13,317.00
Jon D Hecht	Senior Vice President	\$690	4.3	2,967.00
Sam J Canniff	Senior Vice President	\$645	164.7	106,231.50
Kristina Galbraith	Senior Vice President	\$645	12.6	8,127.00
Fernando O Silva	Senior Vice President	\$645	15.7	10,126.50
Andrew D DePalma	Vice President	\$515	207.7	106,965.50
Sam K Lemack	Vice President	\$515	200.1	103,051.50
Nate A Simon	Vice President	\$515	69.9	35,998.50
Tammy Brewer	Vice President	\$450	5.5	2,475.00
Brooke F Filler	Vice President	\$445	9.2	4,094.00
Melanie McCabe	Vice President	\$415	39.3	16,309.50
Mary B Betik	Paraprofessional	\$315	60.0	18,900.00
Barbara J Ferguson	Paraprofessional	\$315	42.8	13,482.00
Total Professional Hours and Fees			1,558.6	\$ 1,087,693.50
Less 50% Travel Fees				-
Subtotal				\$ 1,087,693.50
Less 20% Holdback				(217,538.70)
Invoice Total				\$ 870,154.80
Average Billing Rate				\$ 697.87

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD JUNE 1, 2020 THROUGH JUNE 30, 2020**

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	106.3	\$ 94,305.00
103	Cash Management	187.1	99,063.00
104	Communication with Interested Parties	178.6	91,358.00
105	U.S. Trustee / Court Reporting Requirements	28.8	17,597.50
106	Business Analysis & Operations	542.6	437,747.00
109	Claims Process	40.0	13,360.00
110	Special Projects	97.9	62,583.50
112	Retention and Engagement Administration	12.0	10,897.00
113	Fee Statements and Fee Applications	79.4	45,064.50
114	Court Hearings	7.7	7,453.00
115	Forensic Analysis	278.2	208,265.00
		1,558.6	\$ 1,087,693.50
		Average Billing Rate	\$ 697.87

ALIXPARTNERS, LLP

SUMMARY OF EXPENSES
FOR THE PERIOD JUNE 1, 2020 THROUGH JUNE 30, 2020

EXPENSE CATEGORY	EXPENSE
Other	\$ 193.79
Total	\$ 193.79

AlixPartners, LLP (“AlixPartners”), as Financial Advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Tenth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period June 1, 2020 through June 30, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* (Docket No. 528) and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$1,087,693.50, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$193.79, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$870,154.80 (80% of \$1,087,693.50) and expenses in the amount of \$193.79, for a total amount of \$870,348.59.

Dated: August 11, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

AlixPartners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/01/20	JD	Call with R. Aleali (Purdue) re: catch up after ad hoc committee call and catch up on open items and timeline.	0.30
06/01/20	JD	Call with R. Aleali (Purdue) re: catch up on outstanding issues	0.20
06/02/20	LJD	Call with PJT RE: case status update.	0.30
06/04/20	LJD	Weekly planning meeting with L. Donahue, J. DelConte, G. Koch (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, J. O'Connell, T. Melvin (all PJT) J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: go forward planning and progress update.	0.80
06/04/20	LJD	Review UCC letter to the court.	0.50
06/04/20	GJK	Weekly planning meeting with L. Donahue, J. DelConte, G. Koch (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, J. O'Connell, T. Melvin (all PJT) J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: go forward planning and progress update.	0.80
06/04/20	JD	Weekly planning meeting with L. Donahue, J. DelConte, G. Koch (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, J. O'Connell, T. Melvin (all PJT) J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: go forward planning and progress update.	0.80
06/04/20	JD	Review agenda and status updates prior to weekly update call.	0.20
06/04/20	JD	Review Purdue staffing needs.	0.30
06/05/20	JD	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	JD	Review status of ongoing work streams in advance of weekly call.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/05/20	JD	Correspondence with R. Brown (Purdue) re: professional fee accruals for April.	0.50
06/05/20	JD	Review latest updated compensation summary from I. Arana (AlixPartners) for Willis Towers Watson.	0.60
06/05/20	RDS	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	NAS	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	GJK	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	JDH	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	LJD	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	LJD	Call with PJT RE: case status.	0.30
06/05/20	LJD	Review latest Purdue staffing needs.	0.40
06/05/20	MFR	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	FOS	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	SKL	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/08/20	GJK	AlixPartners) re: Weekly update call	
06/08/20	GJK	Update to draft email to Mundipharma including calls with C Oluwole (DPW).	2.50
06/08/20	GJK	Call with I. McClatchey (Norton Rose) re: overall diligence.	0.30
06/08/20	GJK	Finalize and send email to Mundipharma executives re: outstanding diligence items and need for company responsiveness.	2.50
06/08/20	JD	Correspondence with C. Oluwole, C. Robertson (Davis Polk), J. Turner (PJT), J. DelConte and G. Koch (both AlixPartners) re: Mundipharma diligence.	0.70
06/08/20	JD	Review PII lists for firms to work for the Monitor.	0.40
06/09/20	JD	Provide SAP access list to J. Lowne (Purdue).	0.20
06/09/20	JD	Call with R. Aleali (Purdue) re: case catch up and go forward planning.	0.50
06/09/20	GJK	Walkthrough and provide feedback for updated Mundipharma interim diligence report with new valuation slides.	2.20
06/09/20	GJK	Walkthrough of recent PJT valuation slide updates.	1.30
06/09/20	GJK	Review of third part debt obligations including review of original settlement framework, email exchanges with N. Simon (AlixPartners) on topic.	1.60
06/09/20	LJD	Call with K. Buckfire (Purdue Board Member) RE: case status.	0.40
06/09/20	LJD	Review and discuss Rhodes org doc for presentation to management.	0.60
06/10/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: Purdue staffing.	0.60
06/10/20	GJK	Review and planning re: B. Lea email and Mundipharma	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		diligence next steps.	
06/10/20	GJK	Review of potential changes to interim report finalization based on further diligence per B. Lea (Mundipharma) email.	2.50
06/10/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: Purdue staffing.	0.60
06/10/20	JD	Conversation with C. Robertson (Davis Polk) re: open work streams.	0.30
06/11/20	JD	Weekly update call with J. O'Connell, J. Turner (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, L. Donahue (both AlixPartners) and C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue).	0.80
06/11/20	JD	Draft staffing and work stream plan for Purdue.	0.70
06/11/20	JD	Review various materials to be uploaded to the data room in response to AHC diligence questions.	0.50
06/11/20	JD	Call with R. Aleali (Purdue) re: follow up to weekly call.	0.20
06/11/20	JD	Call with E. Vonnegut (Davis Polk) re: Mundipharma diligence.	0.20
06/11/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) re: data room.	0.20
06/11/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: data room.	0.20
06/11/20	GJK	Review and comment on Analgesic slides for Mundipharma interim report appendix.	0.40
06/11/20	GJK	Update diligence planning based on recent IAC events and potential for management discussions.	3.00
06/11/20	GJK	Draft response to B. Lea (Mundipharma) and seek feedback from advisor group.	2.50
06/11/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		updates to deck and diligence process.	
06/11/20	LJD	Prepare for and attend weekly update call with J. O'Connell, J. Turner (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, L. Donahue (both AlixPartners) and C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue).	1.10
06/11/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: updates to deck and diligence process.	0.20
06/12/20	NAS	Call with J. Turner (PJT), A. Lutchen, E. Vonnegut, C. Robertson (all Davis Polk), G. Koch, J. DelConte, N. Simon (all AlixPartners) re: Mundipharma diligence.	0.60
06/12/20	NAS	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	SJC	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	LJD	Review and discuss revised workstream analysis from team.	0.60
06/12/20	LJD	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	MFR	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	FOS	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma diligence advisors to review	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		latest draft of KPMG tax analysis.	
06/12/20	GJK	Finalize draft email to B. Lea (Mundipharma) based on inputs/edits from advisors.	1.20
06/12/20	GJK	Prepare for and attend call with J. Turner (PJT), A. Lutchen, E. Vonnegut, C. Robertson (all Davis Polk), G. Koch, J. DelConte, N. Simon (all AlixPartners) re: Mundipharma diligence.	0.90
06/12/20	GJK	Review follow up email and documents from C. Tam (Huron).	2.20
06/12/20	GJK	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	JDH	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	RC	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	JD	Call with J. Turner (PJT), A. Lutchen, E. Vonnegut, C. Robertson (all Davis Polk), G. Koch, J. DelConte, N. Simon (all AlixPartners) re: Mundipharma diligence.	0.60
06/12/20	JD	Prepare agenda for weekly AlixPartners update call.	0.40
06/12/20	JD	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	JD	Correspondence with Purdue re: IQVIA data.	0.30
06/12/20	JD	Review Davis Polk workstreams chart.	0.50
06/12/20	JD	Correspondence with N. Simon (AlixPartners) and C. Robertson (Davis Polk) re: claims inquiries.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/15/20	JD	Call with R. Aleali (Purdue) re: work stream updates.	0.60
06/15/20	JD	Correspondence with AlixPartners team and with Purdue IT re: Purdue IT migration and system issues.	0.40
06/15/20	JD	Correspondence with Skadden re: Project Catalyst timeline.	0.20
06/16/20	JD	Correspondence with L. Donahue (AlixPartners) re: updated work streams.	0.30
06/16/20	JD	Call with C. Robertson (Davis Polk) re: Project Catalyst.	0.30
06/16/20	JD	Call with C. Robertson (Davis Polk), J. Doyle, R. Aleali (both Purdue), R. Schnitzler (PJT) re: business development deal.	0.30
06/16/20	JD	Correspondence with Purdue IT and AlixPartners team re: system access.	0.30
06/16/20	JD	Correspondence with AlixPartners legal re: Project Catalyst.	0.50
06/17/20	JD	Review and provide comments on draft agenda for the professional's update call tomorrow.	0.30
06/17/20	JD	Review details re: air service charge schedule from first interim fee app.	0.30
06/17/20	NAS	Purdue IT account migration.	0.40
06/18/20	LJD	Prepare for and attend call with M. Kesselman, R. Aleali, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: weekly update and planning call.	1.20
06/18/20	JD	Call with M. Kesselman, R. Aleali, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) J. DelConte, L.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Donahue, G. Koch (all AlixPartners) re: weekly update and planning call.	
06/19/20	JD	Call with H. Bhattal and J. DelConte (both AlixPartners) re: update on current status of case and ongoing work streams.	1.20
06/19/20	JD	Call with S. Lemack and J. DelConte (both AlixPartners) re: open items.	0.30
06/19/20	JD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	ADD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	KM	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	LJD	Prepare for and attend call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.60
06/19/20	MFR	Prepare for and attend call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.60
06/19/20	SKL	Call with S. Lemack and J. DelConte (both AlixPartners) re: open items.	0.30
06/19/20	SKL	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	SJC	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma,	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	
06/19/20	JDH	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	GJK	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	HSB	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	HSB	Call with H. Bhattal and J. DelConte (both AlixPartners) re: update on current status of case and ongoing work streams.	1.20
06/22/20	HSB	Review Opioid Downside Sensitivity analysis.	0.50
06/22/20	HSB	Review Purdue Pharma presentation prepared by PJT Partners with side-by-side comparison of possible total value from reorganization versus sale scenarios.	3.20
06/22/20	HSB	Review Purdue Business Plan Outline PowerPoint document.	3.00
06/22/20	LJD	Review and comment on cost of continuing in chapter 11 presentation for UCC.	0.80
06/22/20	JD	Correspondence with J. Lowne (Purdue) re: UCC discussion and presentation next steps.	0.30
06/23/20	JD	Review final 1st interim payment amounts in draft order from Davis Polk.	0.20
06/23/20	JD	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/23/20	ADD	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/23/20	LJD	Review comments on UCC deck.	0.30
06/23/20	SKL	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/23/20	HSB	Complete review of Purdue Business Plan Outline PowerPoint document.	1.00
06/23/20	HSB	Complete review of Purdue Pharma presentation prepared by PJT Partners (with side-by-side comparison of possible total value from reorganization versus sale scenarios).	1.00
06/23/20	HSB	Review draft of Mundipharma Interim Report.	3.00
06/23/20	HSB	Review UCC Stipulation and due diligence letter.	0.50
06/23/20	HSB	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/24/20	HSB	Finish review of draft of Mundipharma Interim Report.	0.50
06/24/20	JD	Review and provide comments on latest Nalmafene court reporting.	0.50
06/24/20	JD	Correspondence with management, Davis Polk, PJT, Province, Akin and Jefferies re: scheduling management meetings and delayed emergence presentation and diligence questions.	1.20
06/25/20	JD	Correspondence with FA and IB advisors to set up a call on a potential BD deals.	0.40
06/25/20	LJD	Prepare for and attend board call.	4.30
06/25/20	HSB	Review document with PJT prepared presentation to the UCC from online dataroom.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/25/20	HSB	Review Company document with Overview of Settlement Proposal dated 6/15/2020 from online dataroom.	1.20
06/26/20	HSB	Review audited financial statements for Purdue from online dataroom.	1.20
06/26/20	LJD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	MFR	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	FOS	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	SJC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	RC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	JD	Prepare agenda for weekly AlixPartners update call.	0.40
06/26/20	JD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	ADD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/29/20	JD	Call with R. Aleali (Purdue) re: open diligence items.	0.30
06/29/20	JD	Review correspondence re: IQVIA consent letter.	0.20
06/29/20	JD	Call with C. Robertson (Davis Polk) re: delayed	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		emergence follow up questions.	
06/29/20	HSB	Conduct research and review examples of pharmaceutical b/k liquidation analysis.	1.50
06/30/20	HSB	Conduct research and review examples of pharmaceutical b/k liquidation analysis.	1.00
Total			106.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	2.00	515.00	1,030.00
Sam K Lemack	2.30	515.00	1,184.50
Nate A Simon	2.70	515.00	1,390.50
Fernando O Silva	2.10	645.00	1,354.50
Sam J Canniff	1.80	645.00	1,161.00
Jon D Hecht	2.00	690.00	1,380.00
Ryan D Sublett	0.80	735.00	588.00
HS Bhattal	21.20	840.00	17,808.00
Gabe J Koch	28.60	840.00	24,024.00
Mark F Rule	2.70	910.00	2,457.00
Jesse DelConte	23.40	950.00	22,230.00
Kevin M McCafferty	0.50	950.00	475.00
Richard Collura	1.30	1,090.00	1,417.00
Lisa Donahue	14.90	1,195.00	17,805.50
Total Hours & Fees	106.30		94,305.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/01/20	SKL	Review and reconcile list of indemnitee vendors approved for pre and postpetition payment from C. MacDonald (Purdue) and updated the AP tracker accordingly.	1.10
06/01/20	SKL	Finalize updates to the week ended 05/15 cash report based on feedback provided by E. Nowakowski (Purdue) and circulate for final sign-off and production.	1.60
06/01/20	SKL	Finalize updates to the Purdue and Rhodes forecast-to-actuals re: week ended 05/15 cash report.	1.20
06/01/20	SKL	Create accounts payable release file.	1.30
06/02/20	SKL	Create accounts payable release file.	0.80
06/02/20	SKL	Finalize review of a vendor's executed vendor agreement and updated the AP tracker accordingly so their invoices are released in today's payment run.	1.30
06/02/20	SKL	Finalize review of the docket for the latest restructuring professional fee applications and updated the restructuring fee tracker accordingly.	2.30
06/02/20	SKL	Finalize review of the docket for the latest retained professional fee applications and updated the retained fee tracker accordingly.	1.90
06/02/20	SKL	Prepare updated retained restructuring professional tracker that details the fee applications filed in the second interim fee period and circulate per DPW request.	2.70
06/02/20	SKL	Prepare updated retained professional fee summary and implemented into the latest tracker for DPW review.	1.50
06/03/20	SKL	Review the March flash report and prepared a new version that is non-PEO.	2.00
06/03/20	SKL	Review the latest weekly cash report for outstanding inquiries and prepared list of questions/items for E. Nowakowski (Purdue) and J. Liceaga (TXP) to provide	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		additional insight on.	
06/03/20	SKL	Review the latest Prime Clerk claims summary report and began creating the claims database accordingly.	2.60
06/03/20	SKL	Create accounts payable release file.	0.70
06/04/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.90
06/04/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.30
06/04/20	SKL	Prepare the updated IAC and Investment summaries for the latest weekly cash report and circulate open cash inquiries for E. Nowakowski (Purdue) and J. Liceaga (TXP) to provide additional detail on.	2.00
06/05/20	SKL	Update the Purdue cash summary of the latest weekly cash report and prepared the relevant slides for the cash report accordingly.	1.60
06/05/20	SKL	Update the Rhodes cash summary of the latest weekly cash report and prepared the relevant slides for the cash report accordingly.	1.30
06/05/20	SKL	Continue preparing the final slides of the weekly cash report.	1.40
06/05/20	SKL	Finalize updates to the 05/22 weekly cash report and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.80
06/05/20	SKL	Prepare updated reconciliation and summary of the rebate payments made in the last month and followed-up on open rebate related inquiries.	0.80
06/05/20	SKL	Create accounts payable release file.	0.90
06/08/20	SKL	Begin preparing the next Purdue cash forecast by	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		refreshing the latest summaries and preparing the source files for implementation into the model.	
06/08/20	SKL	Finalize updates to the restructuring professional fee tracker based on the latest fee applications filed on the docket.	1.70
06/08/20	SKL	Finalize updates to the retained professional fee tracker based on the latest fee applications filed on the docket.	1.50
06/08/20	SKL	Review the latest list of reporting inquiries provided by Province and provided update accordingly.	0.80
06/09/20	SKL	Prepare the latest open AP report and updated the OpEx section of the Purdue forecast accordingly.	2.40
06/09/20	SKL	Prepare the latest open AR report and updated the Customer Receipt section of the Purdue forecast accordingly.	2.20
06/09/20	SKL	Review the latest IAC transactions re: weekly cash actuals and updated the latest Purdue 13-week forecast accordingly.	2.10
06/09/20	SKL	Review the March flash report and prepared and non-PEO version of the report accordingly.	2.20
06/10/20	SKL	Review latest updates to the SAP and AP release processes and prepared accounts payable release files.	2.70
06/10/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.20
06/10/20	SKL	Review and reconcile the latest Paysource transactions report, reconciled against the EastWest transaction report, and updated the categorization accordingly.	1.70
06/10/20	SKL	Review and reconcile the latest IAC and investment related transactions and prepared list of open cash inquiries for E. Nowakowski (Purdue) accordingly.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/10/20	SKL	Finalize updates to the Purdue and Rhodes summaries re: weekly cash actuals.	1.00
06/11/20	SKL	Continue to make updates to the sales forecast and implement into the latest Purdue cash forecast.	2.30
06/11/20	SKL	Review and reconcile the full April 2020 financial presentation and began preparing the April flash report accordingly.	2.40
06/11/20	SKL	Finalize reconciliation of the full April 2020 financial presentation and finalized and circulate the April flash report accordingly.	2.70
06/11/20	SKL	Create accounts payable release file.	0.80
06/11/20	SKL	Prepare for and participate in meeting with C. MacDonald (Purdue) re: indemnitee firms and payment process.	1.10
06/12/20	SKL	Finalize updates to the Op. Ex. and AP roll-forward section of the latest Purdue cash forecast.	1.40
06/12/20	SKL	Finalize updates to the Retained professional, Restructuring professional, and Legal fee section of the latest Purdue forecast.	1.90
06/12/20	SKL	Create accounts payable release file.	0.90
06/12/20	SKL	Review latest feedback provided by C. Hobbick (Purdue) and updated the rebate section of the latest weekly cash report accordingly.	1.30
06/12/20	SKL	Review and reconcile the latest information provided by P. Phouthasone (Purdue) re: Rhodes sales, and prepared and circulate the latest Rhodes weekly sales report.	0.90
06/12/20	SKL	Continue to work through and update the Customer Receipts and AR roll-forward section of the latest Purdue forecast.	1.80
06/12/20	SKL	Review and reconcile the latest information provided by	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		E. Nowakowski (Purdue) re: Purdue sales, and prepared and circulate the latest Purdue weekly sales report.	
06/15/20	SKL	Create accounts payable release file.	0.80
06/15/20	SKL	Prepare for and participate in call with I. Arana, S. Lemack (both AlixPartners) re: PPLP rebates in forecast.	0.80
06/15/20	SKL	Continue to finalize review of the latest IAC cash items and followed up with J. Liceaga (TXP) accordingly.	1.30
06/15/20	SKL	Finalize updates to the weekly cash report and circulate the deck for final sign-off.	2.20
06/15/20	SKL	Review and reconcile the latest Purdue rebate tracker and finalized updates to the customer rebate section of the latest cash forecast accordingly.	2.40
06/15/20	SKL	Finalize updates to the Purdue and Rhodes weekly sales reports and circulate to the company for final sign-off.	1.90
06/15/20	JD	Correspondence with J. Lowne (Purdue) and S. Lemack (AlixPartners) re: cash forecast to actual report.	0.30
06/15/20	JD	Review documents uploaded to the Project Catalyst dataroom.	0.70
06/15/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.40
06/16/20	SKL	Review the docket for the latest restructuring professional fee application and updated the Purdue cash forecast accordingly.	1.80
06/16/20	SKL	Review the docket for the latest retained professional fee application and updated the Purdue cash forecast accordingly.	1.70
06/16/20	SKL	Begin to finalize updates to the Op. Ex. portion of the latest 13 week Purdue forecast.	2.10
06/16/20	SKL	Continue to finalize updates to the Op. Ex. portion of the	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		latest 13 week Rhodes forecast.	
06/16/20	SKL	Continue to finalize updates to the customer rebate portion of the latest 13 week Purdue forecast.	1.70
06/16/20	SKL	Create accounts payable release file.	0.70
06/17/20	SKL	Create accounts payable release file.	0.80
06/17/20	SKL	Continue to finalize updates to the customer rebate portion of the latest 13 week Rhodes forecast.	1.50
06/17/20	SKL	Prepare updated weekly sales report for Rhodes and circulate for final sign-off.	1.10
06/17/20	SKL	Finalize updates to the latest Purdue weekly sales report and circulate for final sign-off.	1.20
06/17/20	SKL	Prepare updated critical vendor analysis and circulate vendor breakdown accordingly.	1.50
06/17/20	SKL	Finalize updates to the Purdue cash forecast and updated the deck accordingly.	1.60
06/17/20	SKL	Finalize updates to the Rhodes cash forecast and updated and circulate the deck accordingly.	1.80
06/18/20	SKL	Prepare and circulate the latest cash activity report for the May MOR.	2.30
06/18/20	SKL	Prepare and circulate the latest investment activity report for the May MOR.	2.10
06/18/20	SKL	Prepare and circulate the latest retained professional payment activity report for the May MOR.	2.00
06/18/20	SKL	Review and reconcile the latest Paysource transactions report, reconciled against the EastWest transaction report, and updated the categorization accordingly.	1.60
06/18/20	SKL	Create accounts payable release file.	0.90
06/19/20	SKL	Create accounts payable release file.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/19/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.10
06/19/20	SKL	Review and reconcile the latest IAC and investment related transactions and prepared list of open cash inquiries.	1.70
06/19/20	SKL	Prepare for and participate in call with C. MacDonald (Purdue) to finalize updates and answer questions re: the professional payment piece of the May MOR.	1.10
06/19/20	SKL	Finalize updates to the professional payment piece of the May MOR following today's call with C. MacDonald (Purdue).	0.50
06/19/20	SKL	Update the customer rebate and restructuring professional piece of the latest cash forecast and recirculated accordingly.	1.80
06/19/20	JD	Call with B. Soper (Stretto) re: cash management options.	0.30
06/19/20	JD	Review and provide comments on the latest cash flow forecast.	0.70
06/22/20	JD	Review and comment on latest cash forecast to actual report.	0.70
06/22/20	SKL	Create accounts payable release file.	0.80
06/22/20	SKL	Finalize updates to the week ended 06/05 weekly cash report and circulated for final sign-off.	2.10
06/22/20	SKL	Pulled the latest A/P information from SAP and began updating the Op. Ex. section of the Purdue forecast accordingly.	2.70
06/22/20	SKL	Update the Op. Ex. piece of the Rhodes forecast using the latest A/P information pulled from SAP.	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/22/20	SKL	Review and reconciled the latest rebate tracker and began updating the rebate section of the Purdue forecast accordingly.	2.10
06/22/20	HSB	Review cash forecast prepared by S. Lemack (AlixPartners).	0.30
06/23/20	SKL	Review latest feedback provided on a particular critical vendor's payment inquiry and prepared payment to the vendor accordingly.	1.60
06/23/20	SKL	Pulled the latest A/R information from SAP and began updating the Customer Receipt section of the Purdue forecast accordingly.	2.20
06/23/20	SKL	Update the Customer Receipt section of the Rhodes forecast using the latest A/R information from SAP.	1.90
06/23/20	SKL	Finalize the Customer Rebate and summary sections of the Purdue and Rhodes forecasts and began updating the deck accordingly.	2.10
06/23/20	SKL	Prepare for and participate in discussion with the Prime Clerk team re: claim image inquiries and claim summary review.	0.80
06/23/20	SKL	Create accounts payable release file.	0.70
06/23/20	JD	Call with B. Soper (Stretto) re: cash management options.	0.30
06/24/20	JD	Review and provide comments on latest draft 13 week cash flow forecast.	0.80
06/24/20	SKL	Finalize updates to the IAC and Restructuring/Retained Professional piece of the Purdue and Rhodes forecast and updated the deck accordingly.	2.40
06/24/20	SKL	Create accounts payable release file.	1.00
06/24/20	SKL	Review the latest updates provided for the week ended	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		06/12 weekly cash report and updated the Purdue and Rhodes cash summaries accordingly.	
06/24/20	SKL	Review and reconciled the week ended 06/19 East West report and prepared categorizing information accordingly.	1.80
06/24/20	SKL	Finalize review of the latest Paysource report re: week ended 06/19 weekly cash report and updated the report accordingly.	1.90
06/25/20	SKL	Prepare for and participate in discussion with J. Liceaga (TXP) re: cash forecast interest rates and updated the forecast with the latest information provided.	1.10
06/25/20	SKL	Review and reconciled the latest Restructuring/Retained professional holdback tracker provided by C. MacDonald and ensured the latest cash forecast was updated accordingly.	1.70
06/25/20	SKL	Review and reconciled the latest cash information provided by R. Brown (Purdue) and E. Nowakowski (Purdue) and updated the summaries and IAC sections of the cash report accordingly.	2.40
06/25/20	SKL	Create accounts payable release file.	0.90
06/25/20	JD	Review and provide comments on latest 13 week cash flow draft.	0.40
06/26/20	SKL	Finalize updates to the week ended 06/12 cash report and began putting together the forecast-to-variance slides.	1.70
06/26/20	SKL	Finalize updates to the week ended 06/19 cash report and prepared list of open items for E. Nowakowski and R. Brown (both Purdue) accordingly.	1.80
06/26/20	SKL	Create accounts payable release file.	0.80
06/29/20	SKL	Create accounts payable release file.	0.90
06/29/20	SKL	Continue to follow-up and finalized the IAC transactions	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/29/20	SKL	and IAC summaries of the latest weekly cash report. Review the latest feedback provided by E. Nowakowski (Purdue) and R. Brown (Purdue) and prepared and finalized the forecast-to-actuals piece of the week ended 06/19 weekly cash report.	2.10
06/29/20	SKL	Review the latest feedback provided by E. Nowakowski (Purdue) and R. Brown (Purdue) and continued to finalize the Rhodes and Purdue summaries slides re: week ended 06/12 cash actuals.	1.60
06/29/20	SKL	Review the latest feedback provided by E. Nowakowski (Purdue) and R. Brown (Purdue) and prepared and finalized the forecast-to-actuals piece of the week ended 06/12 weekly cash report.	2.20
06/29/20	HSB	Review weekly cash reports prepared by S. Lemack (AlixPartners) for weeks ended 6/12 and 06/19.	0.80
06/30/20	SKL	Finalize updates to the Purdue and Rhodes IAC summary slides of the week ended 06/19 cash report.	1.20
06/30/20	SKL	Review the April Financial Board Deck provided by E. Nowakowski (Purdue) and prepared the updated non-PEO version of the April Flash report accordingly.	2.70
06/30/20	SKL	Review latest feedback provided on the non-PEO version of the April Flash report and updated accordingly.	2.10
06/30/20	SKL	Review and reconciled latest feedback provided on the week ended 06/12 and 06/19 weekly cash report and revised and recirculated the reports accordingly.	2.50
06/30/20	SKL	Create accounts payable release file.	0.80
06/30/20	JD	Review and provide comments on 6/12 and 6/19 cash forecast to actual reports.	0.80

Total 187.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	180.60	515.00	93,009.00
HS Bhattal	1.10	840.00	924.00
Jesse DelConte	5.40	950.00	5,130.00
Total Hours & Fees	187.10		99,063.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/01/20	JD	Correspondence with R. Aleali (Purdue), M. Kesselman (Purdue), S. Birnbaum (Dechert), J. Turner (PJT) and A. DePalma (AlixPartners) re: status of side by side presentation data room sharing access.	0.80
06/01/20	JD	Participation in call with M. Kesselman (Purdue), M. Huebner, E. Vonnegut (both Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), S. Birnbaum (Dechert) and various ad hoc groups re: side by side analysis presentation.	1.40
06/01/20	JD	Correspondence with A. DePalma (AlixPartners) re: redaction process for diligence materials.	0.30
06/01/20	JD	Review materials from PJT re: AHC diligence requests on latest business plan.	0.40
06/01/20	ADD	Compile documentation in support of diligence request and requested approval from the client to produce documents.	1.20
06/01/20	ADD	Review list of third-parties provided by Davis Polk for relationships with third-party confidentiality implications.	2.40
06/02/20	ADD	Review materials created in response to diligence requests for third party confidential information prior to processing and production.	1.20
06/02/20	ADD	Compile wholesaler/distributor agreements for David Polk's review.	2.30
06/02/20	ADD	Review Committee diligence request list for and provided draft responses.	2.20
06/02/20	ADD	Identify and compile categories of information and materials produced in the dataroom for Davis Polk's Review.	1.60
06/02/20	JD	Review draft responses to Duff & Phelps business plan diligence questions. Review draft excel files to be shared	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		during the call.	
06/02/20	JD	Prepare for and attend call with J. Turner, R. Schnitzler, M. Thomas (all PJT), R. Schwartz, A. Chrysostomou, R. Levy (all Duff & Phelps) re: business plan assumptions.	0.90
06/02/20	JD	Prepare for and attend call with J. Turner, R. Schnitzler, M. Thomas (all PJT), J. Lowne, D. Fogel, E. Ruiz, D. Rosen (all Purdue), R. Schwartz, B. Bartell, J. Feltman (all Duff & Phelps) re: business plan diligence.	1.00
06/04/20	ADD	Prepare updated interested parties list and review entities for inclusion.	1.50
06/04/20	ADD	Identify distribution agreements with Rhodes entities and compile agreements for Davis Polk's diligence team's review.	1.80
06/05/20	ADD	Research material entities for inclusion in third-party entity list requested by Davis Polk.	1.90
06/05/20	JD	Review consolidated model responses from Purdue for AHC questions.	0.40
06/05/20	JD	Review draft question list from FTI for the IACs.	0.30
06/05/20	JD	Review final AHC April business plan diligence responses.	0.90
06/05/20	JD	Call with G. Koch, N. Simon and J. DelConte (all AlixPartners) M. Diaz, B. Bromberg (both FTI), M. Atkinson (Province), J. Turner (PJT) re: IAC diligence response letter.	0.50
06/05/20	ADD	Review list of third-parties provided by Davis Polk for relationships with third-party confidentiality implications.	2.80
06/05/20	GJK	Plan and prepare for call with Advisor group for Mundipharma diligence re: next steps and process for moving forward	1.00
06/05/20	GJK	Call with G. Koch, N. Simon and J. DelConte (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		AlixPartners) M. Diaz, B. Bromberg (both FTI), M. Atkinson (Province), J. Turner (PJT) re: IAC diligence response letter.	
06/05/20	NAS	Call with G. Koch, N. Simon and J. DelConte (all AlixPartners) M. Diaz, B. Bromberg (both FTI), M. Atkinson (Province), J. Turner (PJT) re: IAC diligence response letter.	0.50
06/08/20	JD	Review Province diligence questions and status of various reporting work streams.	0.60
06/08/20	JD	Review side by side analysis to prepare non-PEO version of the deck.	0.50
06/08/20	JD	Review draft ad hoc committee diligence responses prior to posting.	0.30
06/08/20	JD	Review responses from R. Aleali (Purdue) re: documents to post to the data room.	0.20
06/08/20	JD	Review and comment on draft diligence request lists for Mundipharma.	0.50
06/08/20	ADD	Compile and review diligence information provided by client in response to diligence requests.	2.60
06/08/20	ADD	Compile and review agreements in response to diligence request for distributor information.	2.50
06/08/20	ADD	Review and redact third-party information from Purdue Pharma LP board materials in preparation for production in response to diligence requests.	2.30
06/09/20	ADD	Upload documents submitted in response to diligence requests to the data room.	1.10
06/09/20	ADD	Call with PJT, FTI, and HL re: business plan diligence questions.	0.50
06/09/20	ADD	Review and compile information provided by client in	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		response to diligence requests Committees.	
06/09/20	ADD	Review and redact third-party information from Purdue Pharma LP board materials in preparation for production in response to diligence requests.	2.90
06/09/20	ADD	Call with Davis Polk to discuss distributor agreements.	0.40
06/09/20	ADD	Research entity relationships for potential third-party confidentiality implications.	3.20
06/09/20	JD	Review files per request from the ad hoc committee to disclose information from certain PEO files to the committee members.	1.40
06/09/20	JD	Review correspondence from K. McCarthy (Purdue) re: Project Catalyst diligence process. Review updated diligence list and categorization.	0.80
06/10/20	ADD	Review document for potential redactions of third-party information at request of Davis Polk.	0.40
06/10/20	ADD	Compile and review diligence information provided by client in response to diligence requests.	2.70
06/10/20	ADD	Compile and review agreements in response to diligence request for distributor information.	2.60
06/10/20	ADD	Upload documentation processed by the eDiscovery team for the various creditor groups.	1.30
06/10/20	ADD	Review and redact third-party information from Purdue Pharma LP board materials in preparation for production in response to diligence requests.	2.90
06/11/20	ADD	Review and redact third-party information from Purdue Pharma Inc board materials in preparation for production in response to diligence requests.	2.40
06/11/20	ADD	Upload documentation processed by the eDiscovery team for the various creditor groups.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/11/20	ADD	Compile and review agreements in response to diligence request for distributor information.	2.20
06/11/20	ADD	Review materials submitted in response to diligence requests to determine responsiveness to Committee request.	1.60
06/11/20	JD	Review and provide comments on initial draft April flash report.	1.10
06/11/20	JD	Correspondence with R. Aleali (Purdue) and J. Turner (PJT) re: NCSG diligence request to share certain information.	0.30
06/12/20	JD	Review overview of settlement proposal to post to the data room.	0.50
06/12/20	ADD	Upload files provided by Davis Polk to the data room.	1.80
06/12/20	ADD	Review history of diligence requests provided by the committees.	1.20
06/15/20	JD	Correspondence with R. Aleali (Purdue) and T. Melvin (PJT) re: Monitor diligence requests.	0.90
06/15/20	ADD	Call with B. Ferguson, S. Betik, A. DePalma (all AlixPartners) re: third-party confidentiality review	0.70
06/15/20	ADD	Update third-party confidentiality research materials in preparation for team to conduct additional research.	1.50
06/15/20	ADD	Meeting with R. Collura, A. DePalma, S. Canniff (all AlixPartners) re: diligence requests.	1.00
06/15/20	MBB	Call with B. Ferguson, S. Betik, A. DePalma (all AlixPartners) re: third-party confidentiality review	0.70
06/15/20	MBB	Conduct third-party confidentiality review of claims.	2.10
06/15/20	BJF	Call with B. Ferguson, S. Betik, A. DePalma (all AlixPartners) re: third-party confidentiality review.	0.70
06/16/20	BJF	Third party confidentiality research for due diligence	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		request.	
06/16/20	BJF	Research third party confidentiality for due diligence request.	2.30
06/16/20	MBB	Conduct third-party confidentiality review of claims.	1.90
06/16/20	MBB	Review claims database to identify possible duplicate claims.	2.70
06/16/20	ADD	Review documentation submitted in response to diligence requests in preparation for production.	2.70
06/16/20	ADD	Draft correspondence in response to request for files by client.	0.50
06/16/20	JD	Correspondence with AlixPartners team re: audits and transfer pricing.	0.50
06/16/20	JD	Review and provide comments on draft AHC questions and responses.	0.70
06/17/20	JD	Review correspondence from PJT, Davis Polk and management re: updated buyers log.	0.30
06/17/20	JD	Correspondence with PJT and management re: insurance diligence requests from Duff & Phelps.	0.40
06/17/20	MBB	Review claims database to identify possible duplicate claims.	2.70
06/17/20	MBB	Conduct third-party confidentiality review of claims for matching.	2.80
06/17/20	BJF	Third party confidentiality research for due diligence request.	1.80
06/18/20	MBB	Review claims database to identify possible duplicate claims.	2.40
06/18/20	MBB	Review claims database to match with duplicates.	2.80
06/18/20	JD	Correspondence with Davis Polk and PJT re: request from AHC for ability to share certain information with their	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		committee members.	
06/18/20	JD	Review draft AHC diligence questions and responses. Provide comments re: same.	0.40
06/18/20	ADD	Review documentation submitted in response to diligence requests in preparation for production.	2.40
06/19/20	JD	Review latest severance details file per open AHC diligence requests.	0.40
06/19/20	JD	Correspondence with AlixPartners and Purdue re: Project Catalyst diligence request items.	0.30
06/19/20	JD	Review and provide comments on draft ad hoc committee diligence question responses from management.	0.60
06/19/20	MBB	Conduct third-party confidentiality review of claims.	2.90
06/19/20	MBB	Review claims database to identify possible duplicate claims.	2.60
06/19/20	MBB	Review claims database to match with duplicates.	1.90
06/21/20	JD	Correspondence with PJT and Province re: delayed emergence presentation timing.	0.20
06/22/20	JD	Call with Ad Hoc Committee professionals and committee members, Davis Polk (E. Vonnegut, M. Huebner), PJT (J. O'Connell, R. Schnitzler, J. Turner), Purdue (M. Kesselman), Dechert (S. Birnbaum) re: updated side by side presentation.	1.10
06/22/20	JD	Review claims report summary data in response to AHC due diligence questions.	0.50
06/22/20	JD	Correspondence with PJT and Davis Polk re: non-PEO version of the side by side deck to share with various creditor advisors.	0.20
06/22/20	ADD	Add new users to existing creditor groups to the data room and manage data room permissions.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/22/20	MBB	Review claims database to determine duplicate claims and matched.	2.80
06/22/20	MBB	Review claims database to match with duplicates.	2.40
06/23/20	MBB	Review claims database to determine duplicate claims and matched.	2.60
06/23/20	MBB	Review claims database to match with duplicates.	2.90
06/23/20	ADD	Review materials provided in response to diligence requests in preparation for production to the data room.	2.90
06/23/20	ADD	Prepare and format response to HR diligence request.	0.80
06/23/20	JD	Correspondence with various parties in order to schedule a call with the UCC advisors, Debtor advisors and management.	0.70
06/24/20	JD	Review excel diligence files to potentially be shared with the individual victim's group.	0.30
06/24/20	JD	Review and provide comments on various diligence files from Davis Polk that are responsive to outstanding UCC requests.	0.50
06/24/20	ADD	Add new creditor group to data room and update access/permissions accordingly.	2.10
06/24/20	ADD	Research and compile information for tax diligence request.	1.50
06/24/20	MBB	Review claims database to determine duplicate claims and matched.	2.80
06/24/20	MBB	Review claims database to match with duplicates.	2.40
06/25/20	ADD	Upload production of diligence files to Intralinks data room for creditor groups.	0.80
06/26/20	ADD	Upload files provided by Davis Polk eDiscovery team for upload to the data room for the creditor committees.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/26/20	JD	Participate in a call with J. Lowne, M. Ronning, D. Rosen, R. Aleali, M. Kesselman (all Purdue), J. Turner, T. Melvin (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), S. Brauner, A. Preis (both Akin Gump), M. Atkinson, S. Morrison (both Province), L. Schlezinger, K. Sheridan (both Jefferies) re: delayed emergence.	1.00
06/26/20	JD	Prepare for UCC delayed emergence call.	0.30
06/26/20	MBB	Review claims database to determine duplicate claims and matched.	2.10
06/26/20	MBB	Review claims database to match with duplicates.	2.60
06/27/20	JD	Review UCC diligence request and correspondence from management re: same.	0.70
06/28/20	ADD	Upload documents provided by Davis Polk eDiscovery team to the data room.	1.60
06/29/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: delayed emergence information sharing with UCC.	0.80
06/29/20	KM	Attended meeting with J. Turner, R. Schnitzler, T. Melvin (All PJT), M. Atkinson, S. Morrison (both Province), S. Morrison, L. Szlezinger, K. Sheridan (all Jefferies), M. Diaz, B. Bromberg (both FTI), G. Coutts, H. Schenk (both HL), H. Bhattal, J. DelConte, K. McCafferty (all AlixPartners). Discussed Rhodes Updates.	0.90
06/29/20	MBB	Review claims database to determine duplicate claims and matched.	2.80
06/29/20	MBB	Matched duplicate claims in claims database.	2.10
06/29/20	MBB	Review and matched duplicate claims in database.	2.40
06/29/20	JD	Attended meeting with J. Turner, R. Schnitzler, T. Melvin (All PJT), M. Atkinson, S. Morrison (both Province), S. Morrison, L. Szlezinger, K. Sheridan (all Jefferies), M.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Diaz, B. Bromberg (both FTI), G. Coutts, H. Schenk (both HL), H. Bhattal, J. DelConte, K. McCafferty (all AlixPartners). Discussed Rhodes Updates.	
06/29/20	HSB	Attended meeting with J.Turner, R. Schnitzler, T. Melvin (All PJT), M. Atkinson, S. Morrison (both Province), S. Morrison, L. Szlezinger, K. Sheridan (all Jefferies), M. Diaz, B. Bromberg (both FTI), G. Coutts, H. Schenk (both HL), H. Bhattal, J. DelConte, K. McCafferty (all AlixPartners). Discussed Rhodes Updates.	0.90
06/30/20	JD	Correspondence with Province re: open diligence items.	0.30
06/30/20	MBB	Review claims database to determine duplicate claims and matched.	2.90
06/30/20	MBB	Matched duplicate claims in claims database.	2.80
06/30/20	ADD	Compile and format third-party confidential disclosure agreements to document confidentiality provisions.	2.90
06/30/20	ADD	Compile licensing and assignment agreements at client's request.	0.90
Total			178.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Mary B Betik	59.10	315.00	18,616.50
Barbara J Ferguson	7.50	315.00	2,362.50
Andrew D DePalma	81.70	515.00	42,075.50
Nate A Simon	0.50	515.00	257.50
HS Bhattal	0.90	840.00	756.00
Gabe J Koch	1.50	840.00	1,260.00
Kevin M McCafferty	0.90	950.00	855.00
Jesse DelConte	26.50	950.00	25,175.00
Total Hours & Fees	178.60		91,358.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
06/01/20	JD	Review ordinary course professionals summary materials and correspondence with S. Lemack (AlixPartners) re: same.	0.70
06/01/20	SKL	Review the latest OCP activity and information provided by C. MacDonald (Purdue) and prepared the updated OCP report accordingly.	2.70
06/01/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: and begin preparing the May OCP report.	0.60
06/01/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: and begin preparing the May OCP report.	0.60
06/01/20	MH	Initiate OCP tracking report.	2.40
06/02/20	JD	Correspondence with M. Atkinson, C. Cabello (both Province) and S. Lemack (AlixPartners) re: OCP diligence questions.	0.40
06/03/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest OCP report and updates to the OCP tracker.	0.70
06/03/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest OCP report and updates to the OCP tracker.	0.70
06/03/20	ESK	Review of final versions of the AlixPartners' application and Schedule 1.	0.40
06/04/20	SKL	Review and reconcile the latest OCP updates and prepared updates to the OCP tracker for next month's report.	2.00
06/08/20	SKL	Finalize OCP reconciliation and prepared and finalized updated OCP fee tracker.	2.70
06/08/20	JD	Review details of the ordinary course professional report per Province diligence questions.	0.50
06/10/20	NAS	Submit data requests for insider payments section of May MOR.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
06/11/20	NAS	Review data sources for insider payments section of May 2020 MOR.	0.30
06/11/20	ESK	Review email re: fee application deadlines and procedures.	0.20
06/15/20	NAS	Review data provided for insider payments section of May 2020 MOR.	0.60
06/16/20	NAS	Prepare insider payments section of May MOR.	0.50
06/18/20	NAS	Draft insider payments section of May 2020 MOR.	2.00
06/18/20	NAS	Check insider payments section of May 2020 MOR for accuracy and completeness.	0.40
06/18/20	JD	Review draft May financials for the monthly operating report.	0.40
06/19/20	JD	Review and provide comments on monthly operating report before sending it to the company to sign.	0.70
06/19/20	NAS	Correspondence with J. Lauriat (Purdue) re: insider T&E reimbursements for May MOR.	0.20
06/24/20	ADD	Update Parties in Interest list at request of Davis Polk.	2.10
06/24/20	HSB	Review monthly OCP report prepared by S. Lemack (AlixPartners) and review underlying OCP order.	0.30
06/25/20	SKL	Finalize updates to the May OCP report and circulated to the team for final sign-off.	1.90
06/25/20	SKL	Review and reconciled the latest OCP information provided by C. MacDonald (Purdue) and began preparing the May OCP report accordingly.	1.30
06/26/20	SKL	Review the latest feedback provided on the May OCP report and prepared and circulated updated report accordingly.	1.30
06/26/20	JD	Review and provide comments on monthly ordinary course professional report.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
06/29/20	SKL	Review latest updates provided by D. Consla (DPW) and revised and circulated updated OCP report accordingly.	1.10
Total			<u>28.80</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	2.10	515.00	1,081.50
Sam K Lemack	14.30	515.00	7,364.50
Nate A Simon	4.70	515.00	2,420.50
Elizabeth S Kardos	0.60	710.00	426.00
Michael Hartley	3.70	840.00	3,108.00
HS Bhattal	0.30	840.00	252.00
Jesse DelConte	3.10	950.00	2,945.00
Total Hours & Fees	28.80		17,597.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/01/20	IA	Update LTRP 2021 and 2022 estimated payments analysis to include adjusted scenarios requested by WTW and Davis Polk.	2.40
06/01/20	NAS	Review preliminary Mundipharma valuation analysis from PJT.	2.00
06/01/20	NAS	Call with J. Turner, R. Schnitzler, J. Arsic (all PJT), G, Koch, N. Simon (both AlixPartners) re: initial valuation slides for Mundipharma.	0.80
06/01/20	NAS	Consolidate and provide follow-up items related to PJT preliminary Mundipharma valuation discussion.	0.70
06/01/20	NAS	Call with J. Arsic (PJT) re: initial draft of Mundipharma valuation slides.	0.60
06/01/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: initial impressions from preliminary PJT Mundipharma valuation analysis.	0.60
06/01/20	NAS	Draft potential upside slides for Mundipharma diligence presentation.	1.60
06/01/20	GJK	Call with J. Turner, R. Schnitzler, J. Arsic (all PJT), G, Koch, N. Simon (both AlixPartners) re: initial valuation slides for Mundipharma.	0.80
06/01/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: Mundipharma valuation.	0.60
06/01/20	GJK	Review and prepare comments for Mundipharma initial valuation report.	2.50
06/01/20	GJK	Assess potential updates to Mundipharma key findings based on initial valuation deck from PJT.	2.00
06/01/20	GJK	Planning re: Mundipharma interim report draft revisions.	2.00
06/01/20	JD	Review updated side by side analysis prior to call with various ad hoc groups.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/01/20	JD	Review correspondence re: Project Catalyst timeline.	0.60
06/01/20	JD	Review and comment on draft Project Catalyst working group list.	0.20
06/01/20	KM	Next phase planning for Rhodes business planning and org structure initiatives.	0.40
06/01/20	KM	Meeting with A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Shamblen, D. Fogel (both Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	1.20
06/01/20	KM	Meeting with V. Mancinelli (Purdue) re: RP employee mapping.	0.70
06/01/20	KM	Reconcile and augment Rhodes Pharma employee mapping.	1.80
06/01/20	KM	Detailed quality org structure mapping and reconciliation.	1.90
06/01/20	KM	Document and communicate consolidated org changes to D. Lundie (Purdue).	1.30
06/01/20	RDS	Update presentation materials for phase 1 project catalyst.	0.90
06/01/20	RDS	Finalize headcount and organizational charts for Rhodes headcount exercise.	1.40
06/01/20	RDS	Review and make changes to October BoD presentation for Catalyst usage.	0.40
06/01/20	RDS	Review Catalyst VDR request list.	1.10
06/01/20	RDS	Update presentation materials for phase 1 project catalyst.	0.90
06/01/20	RDS	Meeting with A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Shamblen, D. Fogel (both Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/01/20	RDS	Review final V. Mancinelli (Purdue) headcount selections.	0.20
06/01/20	RDS	Correspondence with Catalyst advisors re: process timeline and VDR approval process.	1.40
06/01/20	ADD	Meeting with A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Shamblen, D. Fogel (both Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	1.20
06/01/20	ADD	Review Rhodes critical vendor analysis to identify material counter parties.	2.30
06/01/20	ADD	Update business plan team contact list.	0.40
06/02/20	KM	Call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.70
06/02/20	KM	Assemble updated next steps for operational restructuring.	1.30
06/02/20	KM	Next phase planning for Rhodes org structure initiatives.	0.20
06/02/20	KM	Analysis re: Rhodes diligence question response to HR.	0.50
06/02/20	KM	Analysis re: aggressive Rhodes restructuring opportunities.	1.60
06/02/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes diligence question response to HR.	0.50
06/02/20	KM	Rhodes organizational restructuring review presentation edits and augmentation.	1.00
06/02/20	KM	Analysis re: value creation via Rhodes restructuring.	0.70
06/02/20	RDS	Review VDR uploads for project catalyst.	1.00
06/02/20	RDS	Assemble and refine materials to back up proposed organizational structure and re-engineered processes at RALP.	3.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/02/20	RDS	Call with D. Fogel (Purdue) re: headcount reconciliation.	0.20
06/02/20	RDS	Call with R. Shamblen (Purdue) re: Project Catalyst data requests.	0.20
06/02/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst status update.	0.30
06/02/20	RDS	Call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.70
06/02/20	RDS	Amendments to presentation for Rhodes.	1.00
06/02/20	RDS	Assemble updated next steps for operational restructuring of Rhodes.	1.10
06/02/20	ADD	Review Purdue Pharma LP board minutes from 1999 - 2002 for third-party confidential information.	2.60
06/02/20	JD	Review previous business development board presentations.	0.50
06/02/20	JD	Update latest professional fee tracker in response to questions from Davis Polk. Correspondence with S. Lemack (AlixPartners) re: same.	0.80
06/02/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst status update.	0.50
06/02/20	JD	Call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst status update.	0.30
06/02/20	JD	Review side-by-side deck to share with ad hoc committees on PEO and non-PEO basis.	0.70
06/02/20	JD	Correspondence with S. Daniel and R. Aleali (both Purdue) re: outstanding vendor payment.	0.30
06/02/20	JD	Review Rhodes transformation presentation.	0.70
06/02/20	JD	Prepare for and attend call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transformation plan.	
06/02/20	GJK	Review inputs for upside and downside case analysis for Mundipharma valuation scenario a.	1.90
06/02/20	GJK	Plan for next steps in Mundipharma interim diligence process.	1.80
06/02/20	GJK	Analysis of key missing items from diligence request list for Mundipharma.	2.30
06/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma cash position.	0.40
06/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: current draft of Mundipharma presentation.	0.70
06/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: current draft of Mundipharma presentation.	0.70
06/02/20	NAS	Review prior materials provided related to net debt and cash items and summarize findings for G. Koch (AlixPartners).	2.90
06/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma cash position.	0.40
06/02/20	NAS	Provide Mundipharma diligence items requested by PJT and draft overview slides on KPMG tax analysis.	1.80
06/02/20	LJD	Prepare for and attend call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.80
06/03/20	NAS	Review draft of Mundipharma diligence report from PJT and supporting materials.	1.10
06/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of PJT Mundipharma diligence report.	0.80
06/03/20	NAS	Prepare for and attend call with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/03/20	NAS	Research industry precedents for second adjusted case in Mundipharma business plan model.	1.80
06/03/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: revised draft of valuation section of Mundipharma diligence report from PJT.	0.70
06/03/20	NAS	Review letter from UCC to Judge re: IAC and other diligence requests.	0.40
06/03/20	NAS	Add second adjusted case to Mundipharma business plan model.	0.80
06/03/20	GJK	Calls with I. McClatchey (Norton Rose) re: Mundipharma diligence process.	0.90
06/03/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) and J. Turner (PJT) re: Mundipharma diligence planning.	0.80
06/03/20	GJK	Plan and analysis for Mundipharma diligence process, including follow up email with Advisors and review of process since March.	2.00
06/03/20	GJK	Review and planning re: UCC letter to the Court re: IACs.	1.50
06/03/20	GJK	Review valuation draft update for Mundipharma interim diligence and planning for incorporation with key findings.	2.50
06/03/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: revised draft of valuation section of Mundipharma diligence report from PJT.	0.70
06/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of PJT Mundipharma diligence report.	0.80
06/03/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) and J. Turner (PJT) re: Mundipharma diligence planning.	0.80
06/03/20	JD	Meeting with D. Lundie, J. Lowne, R. Aleali, D. Fogel, R. Shamblen, J. Doyle (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (all AlixPartners), R. Schnitzler, J.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/03/20	JD	Turner (both PJT) re: Project Catalyst update.	
06/03/20	JD	Review draft materials to provide to the ad hoc individual victims' group.	0.70
06/03/20	JD	Prepare draft business development creditor presentation.	2.20
06/03/20	JD	Review Project Catalyst timeline and index comments from management.	0.60
06/03/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: individual victim's document requests.	0.20
06/03/20	ADD	Update liabilities subject to compromise calculation for May financial statements.	2.80
06/03/20	ADD	Download and compile data from Client's SAP system to update liabilities subject to compromise calculation for May.	1.40
06/03/20	ADD	Review Purdue Pharma LP board minutes from 2002 - 2005 for third-party confidential information.	2.80
06/03/20	RDS	Coordinate diligence requests on Project Catalyst.	2.10
06/03/20	RDS	Review Project Catalyst scoring methodology and prepare recommendations.	1.90
06/03/20	RDS	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: data collection for Project Catalyst.	0.60
06/03/20	RDS	Call with K. Laurel, D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: headcount analysis.	0.50
06/03/20	RDS	Meeting with W. DiNicola, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Tech fixed asset review.	0.50
06/03/20	RDS	Assemble and refine materials to back up proposed organizational structure and re-engineered processes at	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		RALP.	
06/03/20	RDS	Meeting with D. Lundie, J. Lowne, R. Aleali, D. Fogel, R. Shamblen, J. Doyle (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (all AlixPartners), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst update.	1.50
06/03/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: individual victim's document requests.	0.20
06/03/20	KM	Create phase 1 offer tracker.	0.70
06/03/20	KM	Meeting with D. Fogel (Purdue), K. Laurel (Purdue) and K. McCafferty, R. Sublett (AlixPartners) re: Rhodes planning.	0.50
06/03/20	KM	Call with K. Laurel, D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: headcount analysis.	0.50
06/03/20	KM	Meeting with W. DiNicola, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Tech fixed asset review.	0.50
06/03/20	KM	Project Catalyst offer tracking process.	0.60
06/03/20	KM	Analysis re: Project Catalyst tracking approach.	0.70
06/03/20	KM	Analysis re: Project Catalyst payroll tracking.	0.30
06/03/20	KM	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: data collection for Project Catalyst.	0.60
06/03/20	RDS	Meeting with D. Fogel (Purdue), K. Laurel (Purdue) and K. McCafferty, R. Sublett (AlixPartners) re: Rhodes planning.	0.50
06/03/20	KM	Meeting with D. Lundie, J. Lowne, R. Aleali, D. Fogel, R. Shamblen, J. Doyle (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (all AlixPartners), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst update.	1.50
06/04/20	KM	Update round 1 tracker re: Project Catalyst.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/04/20	KM	Map offer details re: Project Catalyst.	1.10
06/04/20	KM	Review Rhodes next steps for operational restructuring.	0.20
06/04/20	KM	Review Catalyst Scorecard with D. Lundie, A. Oliveria (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.80
06/04/20	KM	Analysis re: Project Catalyst phase 1 tracker.	1.40
06/04/20	KM	Meeting with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst phase 1 tracker.	0.50
06/04/20	KM	Discussion with R. Sublett, K. McCafferty and J. DelConte (all AlixPartners) re: Rhodes transformation.	0.30
06/04/20	KM	Data review and compilation re: Project Catalyst.	0.90
06/04/20	KM	Analysis re: Rhodes Project Catalyst roster and compensation.	0.90
06/04/20	KM	Meeting with D. Fogel (Purdue) re: Project Catalyst roster and compensation.	0.20
06/04/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes planning.	0.30
06/04/20	KM	Meeting with R. Shamblen, D. Fogel, K. McCarthy (all Purdue), A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	0.50
06/04/20	ADD	Meeting with R. Shamblen, D. Fogel, K. McCarthy (all Purdue), A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	0.50
06/04/20	RDS	Coordinate diligence requests on Project Catalyst.	2.50
06/04/20	RDS	Review Project Catalyst Scorecard / tracker.	1.50
06/04/20	RDS	Finalize AlixPartners assessment of ongoing organizational restructuring.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/04/20	RDS	Meeting with R. Shamblen, D. Fogel, K. McCarthy (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) and R. Schnitzler, J. Wang (both PJT) re: Catalyst VDR Index.	0.50
06/04/20	RDS	Meeting with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst phase 1 tracker.	0.50
06/04/20	RDS	Review Intralinks data structure and prepare correspondence with Rhodes/Purdue team to address deficiencies.	0.80
06/04/20	RDS	Discussion with R. Sublett, K. McCafferty and J. DelConte (all AlixPartners) re: Rhodes transformation.	0.30
06/04/20	RDS	Review Catalyst Scorecard with D. Lundie, A. Oliveria (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.80
06/04/20	RDS	Refine Catalyst scorecard.	1.00
06/04/20	JD	Discussion with R. Sublett, K. McCafferty and J. DelConte (all AlixPartners) re: Rhodes transformation.	0.30
06/04/20	JD	Call with J. Turner (PJT), C. Oluwole, C. Robertson (both Davis Polk), G. Koch and J. DelConte (both AlixPartners) re: UCC letter.	0.40
06/04/20	JD	Correspondence with PJT and Davis Polk re: business development creditor presentation.	0.50
06/04/20	JD	Review UCC letter to Judge Drain re: Sackler discovery efforts.	0.60
06/04/20	JD	Review creditor presentation comments from PJT and Davis Polk. Revise presentation and send around to management for review and approval.	0.70
06/04/20	JD	Review draft presentation to be updated for sharing per AHC diligence questions.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/04/20	JD	Review and provide comments on Rhodes transformation presentation.	1.00
06/04/20	JD	Review IAC diligence summary from G. Koch (AlixPartners).	0.20
06/04/20	JD	Review correspondence from PJT and Purdue re: AHC diligence responses.	0.30
06/04/20	JD	Review draft governmental abatement plan term sheet.	1.60
06/04/20	GJK	Call with J. Turner (PJT), C. Oluwole, C. Robertson (both Davis Polk), G. Koch and J. DelConte (both AlixPartners) re: UCC letter.	0.40
06/04/20	GJK	Continue to develop plan for incorporation of valuation information to Mundipharma interim diligence repeat.	2.00
06/04/20	GJK	Plan for advisor diligence coordination and next steps with focus on meeting information requirements for all advisors.	1.80
06/04/20	GJK	Call with I. McClatchey (Norton Rose) and follow up planning re: Mundipharma diligence.	1.50
06/04/20	GJK	Prepare notes and talking point for weekly planning meeting re: UCC letter to the Court.	0.30
06/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma diligence process and second adjusted case.	0.50
06/04/20	NAS	Finalize second adjusted case in Mundipharma business plan/FCF model.	1.90
06/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to debrief on UCC letter after speaking with counsel.	0.30
06/04/20	NAS	Finish review of letter from UCC to Judge re: IAC and other diligence requests.	0.60
06/04/20	NAS	Research historical precedents for pharmaceutical pricing	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		in China.	
06/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: findings from China pharmaceutical pricing research.	0.40
06/04/20	NAS	Draft adjusted case 2 slides for Mundipharma diligence report.	1.60
06/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to debrief on UCC letter after speaking with counsel.	0.30
06/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: findings from China pharmaceutical pricing research.	0.40
06/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma diligence process and second adjusted case.	0.50
06/04/20	ADD	Review Purdue Pharma LP board minutes from 2006 - 2007 for third-party confidential information.	2.60
06/04/20	ADD	Review third-party entity list for business relationships with Purdue/Rhodes to document potential confidentiality issues.	2.50
06/05/20	ADD	Compile and upload document to the virtual data room and manage access for interested parties.	1.50
06/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Advisor Group call and next steps.	0.40
06/05/20	NAS	Prepare subsequent draft of Mundipharma Adjusted Case 2 slides.	0.50
06/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma Adjusted Case 2 slides and discuss structure of Executive Summary.	0.40
06/05/20	NAS	Review current draft of Mundipharma diligence report to determine what information should be included in Executive Summary.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/05/20	NAS	Draft Mundipharma Executive Summary slides.	2.80
06/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Advisor Group call and next steps.	0.40
06/05/20	GJK	Review updates to draft diligence report and direction on process.	2.00
06/05/20	GJK	Walkthrough of Mundipharma open items including review of FTI discussion topics for call with A. Breabout (Purdue).	2.20
06/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma Adjusted Case 2 slides and discuss structure of Executive Summary.	0.40
06/05/20	IA	Create LTRP 2021 estimated payments summary by employee to be shared with Purdue HR team.	1.30
06/05/20	RDS	Correspondence with management related to Project Catalyst tracker.	1.10
06/05/20	RDS	Manage accounting data uploads to VDR for Project Catalyst.	0.10
06/05/20	RDS	Call with J. Lowne, D. Lundie, J. Doyle, K. ,D. Fogel, R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners), R. Schnitzler (PJT) re: Project Catalyst scorecard and board-level discussion points.	1.00
06/05/20	RDS	Prepare and review updated Org charts for Rhodes Tech.	0.60
06/05/20	KM	Summarize Rhodes org and re-engineering.	0.30
06/05/20	KM	Review Rhodes Tech org charts and employee information re: Project Catalyst.	1.20
06/05/20	ADD	Review materials submitted in response to diligence list for upload to the data room.	2.00
06/05/20	KM	Develop Rhodes org and re-engineering implementation program.	1.90
06/05/20	KM	Review Rhodes Tech data re: Project Catalyst.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/05/20	KM	Review Rhodes Tech org charts and employee information re: Project Catalyst.	0.70
06/05/20	KM	Call with J. Lowne, D. Lundie, J. Doyle, K. ,D. Fogel, R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners), R. Schnitzler (PJT) re: Project Catalyst scorecard and board-level discussion points.	1.00
06/06/20	KM	Reconciliation of Legal review re: Project Catalyst.	0.60
06/06/20	GJK	Draft email to Mundipharma executives, incorporate feedback from J. Turner (PJT).	2.30
06/07/20	GJK	Finalize draft Mundipharma executives email and send to advisor group for review and edits, follow up email to DPW, follow up response to M. Atkinson (Province)	1.80
06/07/20	NAS	Review initial draft of letter to be sent to Mundipharma management.	0.30
06/07/20	RDS	Review Project Catalyst tracker and recent uploads, provide commentary to company-side team.	1.30
06/08/20	RDS	Call with K. McCarthy (Purdue), J. Wang (PJT), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.10
06/08/20	RDS	Review of register for Project Catalyst and prepare analysis.	2.10
06/08/20	ADD	Call with J. DelConte and A. DePalma (AlixPartners) re: diligence process and go forward planning.	0.60
06/08/20	ADD	Call with K. McCarthy (Purdue), J. Wang (PJT), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.10
06/08/20	KM	Project planning with D. Lundie (Purdue) re: Rhodes.	0.60
06/08/20	KM	Call with K. McCarthy (Purdue), J. Wang (PJT), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.10
06/08/20	JD	Call with J. DelConte and A. DePalma (AlixPartners) re: diligence process and go forward planning.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/08/20	JD	Review commentary on open diligence items from Province.	0.30
06/08/20	JD	Research historical liquidation analyses in advance of preparing PPLP liquidation analysis.	0.90
06/08/20	NAS	Review drafts of letter to Mundipharma management and correspondence with other advisors.	1.00
06/08/20	NAS	Review draft list of questions for meeting with A. Breabout (Mundipharma) and other diligence requests.	0.50
06/08/20	NAS	Review revised PJT slides for Mundipharma diligence report.	0.30
06/08/20	IA	Participate in call with C. DeStefano (Purdue), S. Lemack and I Arana (both AlixPartners) re: LTRP sensitivities requested by WTW.	0.80
06/08/20	SKL	Participate in call with C. DeStefano (Purdue), S. Lemack and I Arana (both AlixPartners) re: LTRP sensitivities requested by WTW.	0.80
06/09/20	NAS	Review revised Mundipharma report slides provided by PJT.	1.80
06/09/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) re: Mundipharma report slides from PJT.	0.80
06/09/20	NAS	Correspondence with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	0.40
06/09/20	NAS	Review Mundipharma third party debt to determine treatment in report.	1.30
06/09/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) re: Mundipharma report slides from PJT.	0.80
06/09/20	JD	Review net sales and IMS data from Rhodes per open AHC diligence requests.	0.30
06/09/20	JD	Review final AHC diligence request responses.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/09/20	JD	Review March flash report and comment on non-PEO version edits.	0.70
06/09/20	KM	Call with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.50
06/09/20	KM	D. Fogel, R. Shamblen, K. McCarthy (Purdue), K. McCafferty, R. Sublett (both AlixPartners), J. Wang (PJT) re: VDR.	0.50
06/09/20	KM	Review Rhodes org structure document.	0.80
06/09/20	KM	Review Rhodes R&D restructuring recommendations.	0.90
06/09/20	KM	Rhodes project review with K. McCafferty, R. Sublett (both AlixPartners).	0.60
06/09/20	RDS	Rhodes project review with K. McCafferty, R. Sublett (both AlixPartners).	0.60
06/09/20	RDS	Assemble slides for next steps on org structure of Rhodes.	1.60
06/09/20	RDS	D. Fogel, R. Shamblen, K. McCarthy (Purdue), K. McCafferty, R. Sublett (both AlixPartners), J. Wang (PJT) re: VDR.	0.50
06/09/20	RDS	VDR data uploads and management for Project Catalyst.	1.60
06/09/20	RDS	Review Project Catalyst timeline.	0.80
06/09/20	RDS	Call with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.50
06/09/20	RDS	Correspondence with Catalyst team re: VDR status.	0.40
06/09/20	RDS	Review VDR and legal comment to items.	1.70
06/09/20	RDS	Review Catalyst VDR structure changes.	0.80
06/10/20	RDS	Review material agreements Project Catalyst.	1.40
06/10/20	RDS	Review and edit Project Catalyst Background Presentation.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/10/20	ADD	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/10/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: Project Catalyst.	0.30
06/10/20	RDS	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/10/20	KM	Prepare Rhodes re-organization R&D recommendations and proposed structure.	2.50
06/10/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/10/20	KM	Review offer analysis re: Project Catalyst.	0.50
06/10/20	KM	Planning for Rhodes initiatives.	0.50
06/10/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: Project Catalyst.	0.30
06/10/20	JD	Review response from Mundipharma re: diligence requests.	0.20
06/10/20	JD	Create draft agenda for the professional's and company catch up call tomorrow.	0.50
06/10/20	JD	Correspondence with M. Huebner (Davis Polk) and J. Lowne (Purdue) re: business plan sensitivities.	0.50
06/10/20	JD	Review draft Avrio dashboard.	0.70
06/10/20	JD	Review diligence materials posted to date in the data room.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/10/20	JD	Review summary files provided to date to Willis Towers Watson.	1.00
06/10/20	JD	Review latest professional fee estimates from Purdue.	0.30
06/10/20	JD	Review files to be provided in response to open AHC questions.	0.40
06/10/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to review draft of consolidated Mundipharma diligence report.	0.60
06/10/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma management response to letter sent by diligence advisors.	0.70
06/10/20	NAS	Analyze Mundipharma third party debt balances.	0.80
06/10/20	NAS	Correspondence with Mundipharma management re: diligence process.	0.80
06/10/20	NAS	Revise consolidated Mundipharma diligence report in anticipation of new slides from PJT.	2.40
06/10/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma management response to letter sent by diligence advisors.	0.70
06/10/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to review draft of consolidated Mundipharma diligence report.	0.60
06/10/20	IA	Update LTRP scenarios model to reflect updates requested by WTW.	1.60
06/10/20	IA	Review July retention payments as requested by C. DeStefano (Purdue).	0.80
06/11/20	NAS	Revise latest draft of Mundipharma diligence report.	2.30
06/11/20	NAS	Correspondence with Mundipharma diligence advisors re: response to letter from management.	1.00
06/11/20	JD	Correspondence with R. Aleali and K. McCarthy (both Purdue) re: data room uploads.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/11/20	JD	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40
06/11/20	JD	Call with R. Aleali (Purdue) re: data room process.	0.30
06/11/20	JD	Review historical business plan sensitivities re: opioid low cases.	0.70
06/11/20	KM	Document identification and request re: Project Catalyst liens and encumbrances.	0.20
06/11/20	KM	Document control process and communication re: Project Catalyst.	1.80
06/11/20	KM	Rhodes overview for Project Catalyst.	1.30
06/11/20	KM	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40
06/11/20	KM	Analysis and distribution re: Project Catalyst review tracker for legal review of initial documents.	1.00
06/11/20	KM	Review IP diligence requirements and communication re: Project Catalyst.	0.80
06/11/20	KM	VDR review for Project Catalyst with D. Fogel, K. McCarthy, R. Shamblen (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.60
06/11/20	KM	Analysis re: Project Catalyst legal review and identification of mismatched external opinions.	1.40
06/11/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/11/20	KM	Analysis re: Project Catalyst VDR tracker for legal approval.	0.60
06/11/20	KM	Development of VDR tacking process re: Project Catalyst.	0.80
06/11/20	KM	Call with K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) re: Project Catalyst VDR data tracking and progress.	0.70
06/11/20	KM	Organize Intralinks setup.	0.50
06/11/20	ADD	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40
06/11/20	ADD	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/11/20	ADD	VDR review for Project Catalyst with D. Fogel, K. McCarthy, R. Shamblen (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.60
06/11/20	ADD	Call with K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) re: Project Catalyst VDR data tracking and progress.	0.70
06/11/20	RDS	Call with K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) re: Project Catalyst VDR data tracking and progress.	0.70
06/11/20	RDS	VDR review for Project Catalyst with D. Fogel, K. McCarthy, R. Shamblen (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.60
06/11/20	RDS	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		room setup.	
06/11/20	RDS	Update to Project Catalyst timeline and process.	0.30
06/12/20	RDS	Review correspondence with advisors on investors, gov fundraising efforts and operational cost reduction categories.	1.10
06/12/20	KM	Review of IT software list for VDR.	0.50
06/12/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: catalyst catch up.	0.50
06/12/20	KM	Meeting with N. Davis, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: April dashboard.	0.30
06/12/20	KM	Review and edit Rhodes April dashboard.	0.70
06/12/20	KM	Review of Project Catalyst EE compensation materials.	0.70
06/12/20	KM	VDR document permissioning re: Project Catalyst.	0.20
06/12/20	KM	Meeting with R. Shamblen (Purdue) re: RT overview presentation edits for VDR inclusion.	0.60
06/12/20	KM	RT overview document re: Project Catalyst.	1.70
06/12/20	KM	Meeting with D. Lundie (Purdue) re: Project Catalyst VDR launch timing and needs.	0.20
06/12/20	KM	Meeting with H. Ghnaimeh, D. Fogel (both Purdue) re: IT infrastructure and support for Rhodes Tech.	0.60
06/12/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst VDR and timing.	0.70
06/12/20	RDS	Continue monthly review of Rhodes dashboard.	0.30
06/12/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: catalyst catch up.	0.50
06/12/20	RDS	Meeting with N. Davis, D. Fogel (both Purdue), K.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, R. Sublett (both AlixPartners) re: April dashboard.	
06/12/20	KM	Reconciliation of Legal review re: Project Catalyst.	0.60
06/12/20	KM	Update Legal review for PPLP Legal team re: Project Catalyst.	0.50
06/12/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst VDR and timing.	0.70
06/12/20	KM	Rhodes project planning and communication -- organization restructuring and Project Catalyst.	1.30
06/12/20	JD	Correspondence with PJT and M. Kesselman (Purdue) re: diligence materials re: Rhodes Pharma net sales.	0.30
06/12/20	JD	Review data uploaded to the data room detailing Rhodes Pharma net sales by product.	1.70
06/12/20	JD	Review outstanding Purdue press releases for product level details per request from Purdue legal.	0.80
06/12/20	JD	Review weekly sales reports to be posted to the data room.	0.40
06/12/20	JD	Draft and send responses to diligence requests from Province.	0.70
06/12/20	JD	Correspondence with R. Aleali (Purdue) re: operating reports for the Monitor.	0.30
06/12/20	JD	Review latest Project Catalyst diligence tracker.	0.40
06/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from 6/12 meetings and next steps.	0.60
06/12/20	IA	Call with D. Sims (WTW) re: benefit program requests.	0.50
06/12/20	NAS	Research and respond to vendor inquiry sent by E. Ruiz (Purdue).	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/12/20	NAS	Correspondence with Mundipharma management re: diligence process.	0.60
06/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma diligence advisors to review latest draft of KPMG tax analysis.	1.00
06/12/20	NAS	Draft list of questions in advance of call with A. Breabout (Mundipharma).	0.80
06/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from 6/12 meetings and next steps.	0.60
06/13/20	IA	Update base salary, AIP and LTRP statistics summary as requested by WTW.	1.20
06/14/20	NAS	Review revised Mundipharma valuation slides provided by PJT.	0.50
06/15/20	NAS	Revise latest draft of consolidated Mundipharma diligence report.	1.90
06/15/20	NAS	Review new Mundipharma diligence files including management responses to questions and modified budget.	1.50
06/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to walkthrough revisions to Mundipharma interim diligence report exec summary and next steps.	0.70
06/15/20	NAS	Call with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	0.30
06/15/20	IA	Call with I. Arana, S. Lemack (both AlixPartners) re: PPLP rebates in forecast.	0.50
06/15/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: edits to interim report for distribution to working group.	0.20
06/15/20	IA	Review employee rosters and AIP and LTRP calculations to provide summary data requested by WTW.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/15/20	IA	Update Avrio dashboard for May market share and consumption data.	0.60
06/15/20	GJK	Assess 2019 actuals performance in product format as provided by Huron.	2.00
06/15/20	GJK	Walkthrough of revised Malta model.	3.00
06/15/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: edits to interim report for distribution to working group.	0.20
06/15/20	GJK	Review of 2015 to 2017 decisions re: European transformation.	1.50
06/15/20	GJK	Edit revised Mundipharma interim diligence report exec summary based on latest valuation slides from PJT.	1.00
06/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to walkthrough revisions to Mundipharma interim diligence report exec summary and next steps.	0.70
06/15/20	GJK	Review of revised interim report sent to working group for review.	0.50
06/15/20	JD	Correspondence with J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst.	0.30
06/15/20	JD	Call with C. Oluwole (Davis Polk), J. Turner (PJT), R. Aleali, C. George (both Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Monitor data requests.	0.40
06/15/20	JD	Review data room files for diligence materials re: suboxone sales. Correspondence with PJT and M. Kesselman (Purdue) re: same.	1.80
06/15/20	JD	Correspondence with PJT re: Project Catalyst process letter.	0.50
06/15/20	JD	Review and send April flash report to R. Aleali (Purdue) re: Monitor request.	0.30
06/15/20	JD	Review PBC value comparison update from PJT.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/15/20	JD	Review latest Project Catalyst documents.	1.00
06/15/20	JD	Review Purdue correspondence re: Project Catalyst.	0.30
06/15/20	KM	Analysis and updated re: Project Catalyst VDR tracker.	1.20
06/15/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/15/20	KM	Update and analysis re: Project Catalyst VDR update process and approach for next phase approval and uploading.	0.60
06/15/20	KM	Update and refine re: Project Catalyst VDR tracker.	0.70
06/15/20	KM	Review and manage VDR access list re: Project Catalyst.	0.70
06/15/20	KM	Meeting with D. Fogel, D. Lundie, K. McCarthy (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR launch decision.	0.70
06/15/20	KM	Review Rhodes IT document for Project Catalyst.	0.60
06/15/20	KM	Manage Rhodes and Purdue approvals re: Catalyst VDR launch to external interested parties.	0.90
06/15/20	KM	Review Rhodes environmental document re: Project Catalyst.	1.40
06/15/20	KM	Create document tracker for external review of next wave of documents re: Project Catalyst.	0.90
06/15/20	RDS	Review project catalyst tracker and answer questions.	0.30
06/15/20	ADD	Call with C. Oluwole (Davis Polk), J. Turner (PJT), R. Aleali, C. George (both Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Monitor data requests.	0.40
06/15/20	ADD	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst VDR check-in.	
06/15/20	ADD	Meeting with D. Fogel, D. Lundie, K. McCarthy (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR launch decision.	0.70
06/16/20	ADD	Call with R. Schnitzler, J. Turner (both PJT) , J. DelConte, K. McCafferty, A. DePalma (all and AlixPartners) re: VDR rules, access and diligence tracker.	0.40
06/16/20	ADD	Update project catalyst VDR access list.	0.80
06/16/20	ADD	Call with K. McCarthy, D. Lundi, J. Doyle (all Purdue) and J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: VDR status.	0.40
06/16/20	KM	Modify and edit diligence process re: Project Catalyst.	1.00
06/16/20	KM	Pre-call with K. McCafferty and J. DelConte (both AlixPartners) re: VDR status.	0.20
06/16/20	KM	Call with D. Lundie (Purdue) re: communication process and VDR open issues.	0.20
06/16/20	KM	Track and report re: Project Catalyst next priority of documents for VDR.	0.50
06/16/20	KM	Refine and update Rhodes overview re: Project Catalyst.	0.80
06/16/20	KM	Prepare supporting materials re: diligence submission process for Project Catalyst.	0.70
06/16/20	KM	Create diligence request tracker re: Project Catalyst.	1.30
06/16/20	KM	Review and edit VDR file names re: Project Catalyst.	0.80
06/16/20	KM	Review documents handling and access re: Project Catalyst VDR.	1.30
06/16/20	KM	Call with R. Schnitzler, J. Turner (both PJT) , J. DelConte, K. McCafferty, A. DePalma (all and AlixPartners) re: VDR rules, access and diligence tracker.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/16/20	JD	Call with Purdue (K. McCarthy, D. Lundi, J. Doyle) and AlixPartners (J. DelConte, A. DePalma, K. McCafferty) re: VDR status.	0.40
06/16/20	JD	Update professional fee tracker.	1.10
06/16/20	JD	Pre-call with K. McCafferty and J. DelConte (both AlixPartners) re: VDR status.	0.20
06/16/20	JD	Call with R. Schnitzler, J. Turner (both PJT) , J. DelConte, K. McCafferty, A. DePalma (all and AlixPartners) re: VDR rules, access and diligence tracker.	0.40
06/16/20	JD	Create updated professional fee forecast.	2.30
06/16/20	JD	Correspondence with Purdue re: Project Catalyst timeline.	0.60
06/16/20	JD	Review Duff & Phelps diligence questions re: insurance. Correspondence with PJT re: same.	0.40
06/16/20	KM	Call with K. McCarthy, D. Lundi, J. Doyle (all Purdue) and J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: VDR status.	0.40
06/16/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim diligence report and next steps.	0.70
06/16/20	GJK	Identify and note potential edits/rewrites to Mundipharma interim report for finalization.	3.00
06/16/20	GJK	Review of PJT edits and updates to Valuation section of Mundipharma interim report.	1.50
06/16/20	GJK	Plan and coordinate next phase of Mundipharma diligence based on meetings noted in exchanges with B. Lea (Mundipharma) and potential transition of AlixPartners business plan model.	3.00
06/16/20	IA	Update Avrio dashboard for May consumption and market share.	1.00
06/16/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re:	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/16/20	NAS	Mundipharma interim diligence report and next steps.	
06/16/20	NAS	Review and revise Executive Summary portion of draft Mundipharma diligence report.	1.90
06/16/20	NAS	Review and revise Overview of Diligence Process section of draft Mundipharma diligence report.	1.30
06/16/20	NAS	Review and revise Business Plan Overview portion of draft Mundipharma diligence report.	1.10
06/17/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim report.	0.40
06/17/20	NAS	Review comments from PJT re: draft of Mundipharma diligence report.	0.70
06/17/20	NAS	Revise draft of Mundipharma diligence report following comments from PJT.	0.40
06/17/20	GJK	Review open topics and discussion items for call with A Breabout (Mundipharma).	2.00
06/17/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim report.	0.40
06/17/20	GJK	Plan and coordinate Mundipharma diligence process re: interim report version control and update process.	1.00
06/17/20	GJK	Prepare for Mundipharma SEA regional manager call by reviewing market financials and open questions.	3.00
06/17/20	JD	Call with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners), C. Robertson, E. Vonnegut (both Davis Polk), M. Gibson, M. Florence (both Skadden), J. Turner, R. Schnitzler (both PJT), K. McCarthy, D. Lundie, J. Doyle, J. Lowne, R. Aleali (all Purdue), re: Project Catalyst process.	0.90
06/17/20	JD	Revise professional fee tracker for management review. Correspondence with M. Kesselman (Purdue) and Davis	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Polk re: same.	
06/17/20	JD	Correspondence with PJT and management re: mid-year professional fee forecast and actuals tracker.	2.20
06/17/20	JD	Review draft patent settlement term sheet.	0.30
06/17/20	JD	Review Project Catalyst process letter.	0.40
06/17/20	JD	Review previous four weeks of net sales reports. Review against forecasts.	0.50
06/17/20	JD	Begin drafting delayed bankruptcy emergence presentation per UCC requests.	2.70
06/17/20	KM	Call with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners), C. Robertson, E. Vonnegut (both Davis Polk), M. Gibson, M. Florence (both Skadden), J. Turner, R. Schnitzler (both PJT), K. McCarthy, D. Lundie, J. Doyle, J. Lowne, R. Aleali (all Purdue), re: Project Catalyst process.	0.90
06/17/20	KM	Review re: Catalyst process timeline.	0.50
06/17/20	KM	Aggregate feedback and create tracking summary re: Project Catalyst VDR documents.	1.00
06/17/20	KM	Next phase planning re: Rhodes business planning and initiatives.	0.50
06/17/20	KM	Communicate and prepare supporting materials re: Project Catalyst DD tracking.	1.40
06/17/20	KM	Discussion with D. Lundie (Purdue) re: Project Catalyst negotiations process.	0.10
06/17/20	KM	Email K. McCarthy (Purdue) re: VDR round 2 of documents.	0.10
06/17/20	ADD	Partial participation in a call with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners), C. Robertson, E. Vonnegut (both Davis Polk), M. Gibson, M. Florence	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(both Skadden), J. Turner, R. Schnitzler (both PJT), K. McCarthy, D. Lundie, J. Doyle, J. Lowne, R. Aleali (all Purdue), re: Project Catalyst process.	
06/18/20	KM	Slide creation and deck edits re: presentation to the BOD for D. Lundie (Purdue).	0.90
06/18/20	KM	Analysis re: Project Catalyst.	1.30
06/18/20	KM	Call with A. DePalma, K. McCafferty (AlixPartners), D. Fogel, R. Shamblen, J. Doyle (Purdue), K. McCarthy (Purdue) re: Project Catalyst data room.	0.50
06/18/20	KM	Meeting with D. Fogel, A. Oliveira (both Purdue) re: presentation to the BOD for D. Lundie (Purdue).	0.50
06/18/20	KM	Analysis and review re: Project Catalyst VDR access list and file views.	0.70
06/18/20	KM	Create slide re: Coventry Site and Facilities aerial map for VDR.	0.60
06/18/20	KM	Create support slide re: Project Catalyst process timeline for presentation to the BOD for D. Lundie (Purdue).	1.10
06/18/20	KM	Design approval process re: Project Catalyst process timeline for presentation to the BOD for D. Lundie (Purdue).	0.10
06/18/20	KM	Create summary slide of bidder evaluation process re: presentation to the BOD for D. Lundie (Purdue).	0.70
06/18/20	KM	Analysis and slide creation re: re: presentation to the BOD for D. Lundie (Purdue).	1.20
06/18/20	KM	Review documents re: Project Catalyst VDR content for external legal review.	0.30
06/18/20	JD	Correspondence with Davis Polk, PJT, Skadden and K. McCafferty (AlixPartners) re: Project Catalyst timeline.	0.30
06/18/20	JD	Review initial Project Catalyst teasers and correspondence	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		with various parties. Correspondence with R. Aleali (Purdue) re: same.	
06/18/20	JD	Finalize first draft of presentation on the potential negative consequences of a delayed bankruptcy emergence.	3.10
06/18/20	JD	Review latest business development presentation and recirculate it to the group for final sign off.	0.40
06/18/20	JD	Review and provide diligence materials to M. Kesselman (Purdue) re: Suboxone net sales forecasts.	0.60
06/18/20	JD	Review draft Rhodes board presentation slides.	0.30
06/18/20	JD	Review updated Project Catalyst process letter.	0.20
06/18/20	JD	Review draft non-PEO version of the side by side deck to be shared with creditors.	0.50
06/18/20	GJK	Review and comment on N. Simon (AlixPartners) potential edits to Mundipharma interim report executive summary section.	1.20
06/18/20	GJK	Call with M. Kesselman, R. Aleali, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: weekly update and planning call.	1.00
06/18/20	GJK	Walkthrough of Malta model and Mundipharma schedule of releases of Balance Sheet and Cash Forecast, EY reports and LEK report.	2.50
06/18/20	GJK	Review and check of financials being presented in draft Mundipharma interim report for finalization.	3.00
06/18/20	NAS	Revise draft of Mundipharma diligence report.	0.30
06/18/20	ADD	Call with A. DePalma, K. McCafferty (AlixPartners), D. Fogel, R. Shamblen, J. Doyle (Purdue), K. McCarthy	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(Purdue) re: Project Catalyst data room.	
06/19/20	IA	Review and send calculated 2020 severance numbers requested by J. Lowne (Purdue).	0.80
06/19/20	IA	Update cash flow model output tabs to refresh and roll forecast forward as actuals are loaded.	2.20
06/19/20	IA	Update cash flow model to include latest changes on assumption and comments from AlixPartners team.	1.90
06/19/20	GJK	Finalize draft Mundipharma interim diligence report executive summary and valuation sections.	3.00
06/19/20	GJK	Finalize Mundipharma interim report key findings and diligence process sections.	3.00
06/19/20	GJK	Finalize Mundipharma interim report appendix section.	1.00
06/19/20	GJK	Final review and send out of Mundipharma interim report to L Donahue and J. DelConte (both AlixPartners).	1.10
06/19/20	JD	Create updated summary of professional fee actuals per client request.	0.90
06/19/20	JD	Review comments from commercial and market access teams on presentation on the costs of delayed emergence from bankruptcy. Update presentation to reflect these comments.	1.00
06/19/20	JD	Review updated Project Catalyst diligence request tracker.	0.20
06/19/20	KM	Create process and documentation re: Project Catalyst due diligence request and communication process.	0.80
06/19/20	KM	Document management re: Project Catalyst.	0.70
06/19/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT), and external party re: Project Catalyst due diligence process.	0.50
06/19/20	KM	Analysis re: external party VDR access summary for calls.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/19/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT), and third party re: Project Catalyst due diligence process.	0.50
06/19/20	KM	Analysis re: third party VDR access summary for bidder calls.	0.70
06/19/20	KM	Document management re: Project Catalyst.	0.30
06/19/20	KM	Manage VDR approval and access re: Project Catalyst.	0.30
06/19/20	KM	Discussion with D. Fogel (Purdue) re: historical quarterly financial files for Project Catalyst.	0.10
06/19/20	KM	Document tracking and new document planning re: Project Catalyst.	0.40
06/19/20	KM	Analysis re: Project Catalyst VDR access.	0.30
06/19/20	KM	Document management re: Project Catalyst.	1.20
06/19/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT), and external party re: Project Catalyst due diligence process.	0.50
06/20/20	JD	Review updated delayed emergence presentation and circulate to the broader group for comment.	0.80
06/20/20	JD	Review updated business development deal presentation.	0.30
06/22/20	JD	Review updated side by side presentation in advance of AHC meeting.	0.40
06/22/20	JD	Review final business development presentation before uploading for creditor advisors.	0.50
06/22/20	JD	Review and edit latest delayed bankruptcy emergence presentation.	0.40
06/22/20	JD	Correspondence with PJT, Davis Polk and Purdue management re: open questions and comments on delayed bankruptcy emergence presentation.	1.20
06/22/20	JD	Correspondence with Davis Polk and PJT re: tax basis analysis.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/22/20	JD	Update delayed bankruptcy presentation per comments from Davis Polk and management.	0.80
06/22/20	JD	Review correspondence re: Project Catalyst data room access.	0.20
06/22/20	JD	Review pdf version of long term plan model output to be shared with the committee advisors.	0.30
06/22/20	KM	Review and edit documentation re: Project Catalyst inspections and APR requests.	1.10
06/22/20	KM	Call with R. Shamblen (Purdue) re: inspections and APR requests.	0.30
06/22/20	KM	Review and edit documentation re: Project Catalyst inspections and APR requests.	0.30
06/22/20	KM	Update and refine re: Project Catalyst VDR tracker.	0.40
06/22/20	KM	Call with J. Northington (Purdue) re: quality reports and org restructuring.	0.30
06/22/20	KM	Manage VDR document flow and approval re: Project Catalyst.	0.60
06/22/20	GJK	Call with I. McClatchey (Norton Rose) re: current diligence status, follow up email to working group.	0.60
06/22/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: diligence process and upcoming interviews.	0.30
06/22/20	GJK	Review diligence responses for China market provided by Huron/Mundipharma and open items.	1.20
06/22/20	GJK	Assess Mundipharma business plan model drivers for updates based on upcoming calls and proposed information releases.	2.00
06/22/20	GJK	Review and note key items from EY QOE/VDD reports as potential discussion points for EY call.	2.50
06/22/20	GJK	Update planning and coordination for Mundipharma	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence, including new calls/meetings scheduled and new information.	
06/22/20	NAS	Review updates to Mundipharma diligence process provided by advisors.	0.30
06/22/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: diligence process and upcoming interviews.	0.30
06/23/20	GJK	Prepare for call with EY re: Mundipharma.	0.60
06/23/20	GJK	Call with B. Bromberg (FTI) re: EY progress.	0.20
06/23/20	GJK	Update notes for Mundipharma diligence report phase two.	1.50
06/23/20	GJK	Reassessment and prioritization of open items for Mundipharma diligence finalization.	3.00
06/23/20	GJK	Call with EY and other advisors re: EY progress on Mundipharma audit and related matters.	0.50
06/23/20	JD	Review draft Mundipharma diligence report from G. Koch, N. Simon (both AlixPartners) and PJT.	2.20
06/23/20	JD	Review and incorporate comments from management into the delayed emergence presentation. Finalize report for production to creditors.	0.80
06/23/20	JD	Review latest attrition numbers and voluntary resignation data.	0.40
06/23/20	JD	Call with J. Lowne (Purdue) re: delayed emergence scenarios.	0.20
06/23/20	JD	Call with R. Aleali (Purdue) re: open diligence items.	0.20
06/23/20	JD	Review and provide HR SAP information to management.	0.30
06/23/20	JD	Correspondence with management re: payment of prepetition amounts owed on behalf of an assumed lease.	0.30
06/23/20	JD	Review draft market access question responses in	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		advance of call with the UCC.	
06/23/20	KM	Create and document re: Project Catalyst VDR tracking process and cadence for Purdue and Rhodes team.	0.40
06/23/20	KM	Review VDR process flow with K. McCafferty, R. Sublett (both AlixPartners).	0.30
06/23/20	KM	Manage VDR document flow and approval re: Project Catalyst.	1.30
06/23/20	KM	Call with R. Schnitzler (PJT) re: Project Catalyst diligence document tracking and sharing.	0.30
06/23/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT) re: data room access for Project Catalyst.	0.70
06/23/20	KM	Review document re: Project Catalyst financial information.	0.40
06/23/20	KM	Call with R. Shamblen, W. DiNicola (both Purdue) re: operations and finance diligence document requests.	0.60
06/23/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.00
06/23/20	KM	Update due diligence document tracker re: third party inquiries and questions.	1.20
06/23/20	RDS	Review VDR process flow with K. McCafferty (AlixPartners).	0.30
06/23/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.00
06/24/20	KM	Manage VDR document flow and approval re: Project Catalyst.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/24/20	KM	Meeting with D. Lundie, K. McCarthy (both Purdue), R. Schnitzler (PJT) re: Project Catalyst diligence request management.	1.00
06/24/20	KM	Update due diligence document tracker re: third party inquiries and questions.	1.00
06/24/20	KM	Analysis re: Project Catalyst.	1.50
06/24/20	KM	Document and user management re: Project Catalyst.	1.30
06/24/20	KM	Call with R. Shamblen (Purdue) re: RT diligence data for capacity utilization and throughput.	0.80
06/24/20	JD	Correspondence with management and J. Turner (PJT) re: professional fees in a sale scenario.	0.50
06/24/20	JD	Finalize and process delayed emergence presentation to be uploaded to the data room.	0.60
06/24/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
06/24/20	JD	Review PPI Board meeting agenda and preread materials.	1.50
06/24/20	GJK	Analysis of 2020 open spend based on Mundipharma spend to date guidance.	2.00
06/24/20	GJK	Update notes and analysis for Mundipharma key findings report based on information provided by A Breabout (Mundipharma).	2.50
06/24/20	GJK	Call with A Breabout (Mundipharma) re: business plan, 2019 performance and transaction.	1.70
06/24/20	GJK	Call with I. McClatchey (Norton Rose) re: call with Mundipharma CFO and potential next steps based on call.	0.40
06/24/20	GJK	Prepare for call with A Breabout (Mundipharma).	1.00
06/24/20	IA	Update LTRP analysis for edits requested by WTW.	0.80
06/25/20	GJK	Call with Mundipharma Latam management re: Latam	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		performance.	
06/25/20	GJK	Prepare for Mundipharma Latam call.	0.30
06/25/20	GJK	Reevaluate Mundipharma Latam projections based on Latam call.	1.80
06/25/20	GJK	Analysis of Mundipharma projections and findings based on new diligence calls.	3.00
06/25/20	JD	Participate in PPI Board meeting.	3.50
06/25/20	JD	Call with C. Robertson (Davis Polk) re: board meeting follow up.	0.20
06/25/20	JD	Update HR roster for schedule with only VPs and above.	0.30
06/25/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.40
06/25/20	KM	Call with R. Shamblen (Purdue) re: document approval process.	0.60
06/25/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), D. Fogel (Purdue) re: financial information for Project Catalyst.	0.40
06/25/20	KM	Manage VDR document flow and communications re: Project Catalyst.	0.30
06/25/20	KM	Call with K. McCarthy, R. Aleali, J. Doyle, D. Fogel (all Purdue), R. Schnitzler (PJT), Skadden, and Arnold & Porter re: supply contracts for Project Catalyst.	1.00
06/25/20	KM	Manage VDR document flow and approval re: Project Catalyst.	2.00
06/25/20	KM	Document creation re: Project Catalyst.	0.70
06/25/20	KM	Inventory analysis re: Project Catalyst.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/25/20	KM	Manage VDR document flow and communications re: Project Catalyst.	0.60
06/25/20	KM	Meeting with D. Fogel, R. Shamblen, J. Doyle (all Purdue) re: Project Catalyst diligence response generation and review.	1.00
06/25/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.40
06/25/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), D. Fogel (Purdue) re: financial information for Project Catalyst.	0.40
06/25/20	ADD	Review business development agreements to compile the list of entities with active confidentiality provisions.	2.30
06/26/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance Documents for VDR.	1.00
06/26/20	ADD	Meeting with D. Fogel, R. Shamblen, W. DiNicola, D. Lundie (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: approval of financial information for VDR.	0.50
06/26/20	KM	Communicate VDR document flow and approval re: Project Catalyst.	0.40
06/26/20	KM	Manage VDR document approval re: Project Catalyst.	0.20
06/26/20	KM	Continue review of regulatory documents re: Project Catalyst.	0.60
06/26/20	KM	Call with R. Schnitzler (PJT) re: VDR communication process to Bidders.	0.30
06/26/20	KM	Manage VDR document flow and approval re: Project Catalyst.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/26/20	KM	Meeting with D. Fogel, R. Shamblen, W. DiNicola, D. Lundie (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: approval of financial information for VDR.	0.50
06/26/20	KM	Review of financial diligence documents re: Project Catalyst.	0.30
06/26/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance Documents for VDR.	1.00
06/26/20	KM	Review of regulatory documents re: Project Catalyst.	0.50
06/26/20	JD	Correspondence with K. Galski and M. Ronning (both Purdue) re: opioid scenarios.	1.10
06/26/20	JD	Call with J. Turner (PJT) re: post-UCC meeting follow ups.	0.30
06/26/20	JD	Call with J. Lowne (Purdue) re: downside sensitivity scenario assumptions.	0.50
06/26/20	JD	Correspondence with PJT re: UCC call diligence follow ups.	0.70
06/26/20	JD	Review certain market access materials per UCC diligence requests.	0.50
06/26/20	GJK	Plan and coordinate for Mundipharma diligence calls and updated information requests.	2.50
06/26/20	GJK	Call with Mundipharma SEA region GM re: SEA business performance and planning.	1.00
06/26/20	GJK	Prepare for call with Mundipharma SEA region GM re: SEA business performance and planning.	0.80
06/26/20	GJK	Walkthrough and assessment of new Mundipharma material uploaded to data room.	3.00
06/26/20	IA	Prepare 2021 LTRP payment detail by employee for non-insiders requested by WTW.	0.70
06/27/20	GJK	Call with M. Atkinson (Province) re: Mundipharma	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transaction plans.	
06/27/20	GJK	Review and add to proposed questions to send in advance to Huron for call with A Martinez (Mundipharma).	1.00
06/28/20	JD	Correspondence with Province, PJT and Purdue re: providing certain materials to UCC members under the protective order.	0.80
06/29/20	JD	Correspondence with J. Doyle and R. Aleali (both Purdue) re: business development deal next steps.	0.40
06/29/20	JD	Call with J. Lowne (Purdue) re: business plan refresh.	0.30
06/29/20	KM	Manage and schedule interviews re: Project Catalyst updates.	0.70
06/29/20	KM	Call with D. McGuire (Purdue) re: supply chain org restructuring.	0.30
06/29/20	KM	Call with A. DePalma and K. McCafferty (AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	1.00
06/29/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, K. McCarthy (all Purdue), R. Schnitzler (PJT) re: interview preparation and process.	1.00
06/29/20	KM	Analysis and diligence management re: Project Catalyst diligence process.	0.80
06/29/20	KM	Interview scheduling and coordination re: Project Catalyst interviews.	1.20
06/29/20	KM	Call with D. Fogel (Purdue) re: financial diligence request details and interview expectations.	0.60
06/29/20	KM	Update due diligence document tracker re: new due diligence inquiries and questions.	0.20
06/29/20	ADD	Call with A. DePalma and K. McCafferty (AlixPartners), E.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	
06/29/20	ADD	Review business development agreements from 2010 through 2013 to document parties and confidentiality provisions.	2.80
06/29/20	ADD	Review business development agreements from 2014 through 2016 to document parties and confidentiality provisions.	3.10
06/29/20	GJK	Plan for Mundipharma diligence meetings and next steps in process.	3.00
06/29/20	GJK	Email to/from J. Arsic (PJT) and J. DelConte (AlixPartners) re: interim report draft.	0.50
06/29/20	GJK	Review of Mundipharma draft for edits based on feedback.	1.50
06/29/20	GJK	Analysis of Europe product information and potential model changes for Mundipharma business plan model.	2.00
06/29/20	JD	Review consolidated responses to open UCC delayed emergence diligence questions.	0.80
06/29/20	JD	Correspondence with Davis Polk re: Project Catalyst process.	0.30
06/29/20	JD	Call with J. Lowne (Purdue) re: delayed emergence diligence questions.	0.20
06/29/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: definition of market participants under the protective order.	0.50
06/29/20	JD	Review draft responses and materials provided in response to open UCC questions on the delayed emergence presentation.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/29/20	JD	Review voluntary attrition details and attrition calculations.	0.70
06/30/20	JD	Review and provide comments on April non-PEO monthly flash report.	0.60
06/30/20	JD	Correspondence with J. Lowne (Purdue) and J. Turner, R. Schnitzler (PJT) re: business plan refresh.	0.70
06/30/20	JD	Review and provide comments on updated non-PEO April draft flash report.	0.30
06/30/20	JD	Call with J. Lowne (Purdue) re: open diligence items.	0.20
06/30/20	JD	Correspondence with Purdue re: attrition numbers and details on exit interviews.	0.40
06/30/20	JD	Review latest IAC diligence report.	1.50
06/30/20	JD	Correspondence with Davis Polk and management re: responding to UCC diligence requests.	0.50
06/30/20	JD	Review various 2018 tax returns.	0.40
06/30/20	JD	Create analysis of attrition rates in response to UCC diligence questions.	1.00
06/30/20	JD	Review latest information posted to the Project Catalyst data room.	0.50
06/30/20	JD	Call with R. Aleali (Purdue) re: open diligence items and sharing information with certain parties.	0.50
06/30/20	GJK	Prepare for call with A Martinez (Mundipharma).	0.50
06/30/20	GJK	Calls with I. McClatchey (Norton Rose) re: Mundipharma diligence process.	1.00
06/30/20	GJK	Review of product level Europe market assumptions based on call with A. Martinez (Mundipharma).	3.00
06/30/20	GJK	Call with A Martinez (Mundipharma) re: Europe region performance.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/30/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Wang, E. Schnitzler (both PJT), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR Check-In meeting.	0.70
06/30/20	KM	Manage VDR document flow and communications re: Project Catalyst.	1.10
06/30/20	KM	Coordinate questions and interview process re: Project Catalyst.	0.10
06/30/20	KM	Virtual working session with A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst due diligence status update and compilation of diligence responses.	1.80
06/30/20	KM	Update, edit and circulate due diligence interview guide to internal team re: Project Catalyst.	1.20
06/30/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Wang, E. Schnitzler (both PJT), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR Check-In meeting.	0.70
06/30/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, K. McCarthy (all Purdue), R. Schnitzler (PJT) re: interview preparation and process.	1.00
06/30/20	HSB	Review monthly PEO and non PEO versions of April Flash report prepared by S. Lemack (AlixPartners).	0.60
Total			542.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	44.40	515.00	22,866.00
Sam K Lemack	0.80	515.00	412.00
Nate A Simon	61.60	515.00	31,724.00
Isabel Arana de Uriarte	19.30	690.00	13,317.00
Ryan D Sublett	55.20	735.00	40,572.00
Gabe J Koch	131.90	840.00	110,796.00
HS Bhattal	0.60	840.00	504.00
Kevin M McCafferty	137.80	950.00	130,910.00
Jesse DelConte	90.20	950.00	85,690.00
Lisa Donahue	0.80	1,195.00	956.00
Total Hours & Fees	542.60		437,747.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
06/03/20	ADD	Meeting with A. DePalma, S. Lemack (both AlixPartners) to review the Prime Clerk claims summary report and discuss next steps re: claims management.	1.20
06/03/20	SKL	Meeting with A. DePalma, S. Lemack (both AlixPartners) to review the Prime Clerk claims summary report and discuss next steps re: claims management.	1.20
06/18/20	SKL	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/18/20	BJF	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/18/20	MBB	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/18/20	ADD	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/19/20	MBB	Meeting with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: status of claims and matching project.	0.40
06/19/20	BJF	Match vendor names for claims reconciliation.	2.80
06/19/20	BJF	Meeting with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: status of claims and matching project.	0.40
06/19/20	SKL	Meeting with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: status of claims and matching project.	0.40
06/22/20	BJF	Third party confidentiality research for due diligence request.	2.80
06/23/20	BJF	Third party confidentiality research for due diligence request.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
06/23/20	BJF	Research third party confidentiality for due diligence request.	2.60
06/23/20	BJF	Continue third party confidentiality research for due diligence request.	2.10
06/23/20	BJF	Correspond with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: matching updates.	0.40
06/25/20	BJF	Third party confidentiality research for due diligence request.	2.40
06/25/20	BJF	Research third party confidentiality for due diligence request.	2.70
06/26/20	BJF	Third party confidentiality research for due diligence request.	2.70
06/26/20	BJF	Research third party confidentiality for due diligence request.	2.40
06/26/20	BJF	Continue third party confidentiality research for due diligence request.	1.80
06/29/20	BJF	Third party confidentiality research for due diligence request.	2.70
06/29/20	BJF	Research third party confidentiality for due diligence request.	1.80
06/30/20	BJF	Third party confidentiality research for due diligence request.	2.90
06/30/20	BJF	Research third party confidentiality for due diligence request.	1.40
Total			40.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Mary B Betik	0.90	315.00	283.50
Barbara J Ferguson	35.30	315.00	11,119.50
Andrew D DePalma	1.70	515.00	875.50
Sam K Lemack	2.10	515.00	1,081.50
Total Hours & Fees	40.00		13,360.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/12/20	KG	Prepare eleventh production for delivery.	2.20
06/15/20	ADD	Review and compile materials for Project Catalyst data room.	2.10
06/15/20	ADD	Prepare project catalyst data room for internal and third-parties review.	1.60
06/15/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.60
06/15/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.60
06/16/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst data room management.	1.20
06/16/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst data room management.	1.20
06/16/20	ADD	Prepare Project catalyst data room to open outside parties.	2.80
06/16/20	KG	Load third party production into Relativity. Update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.20
06/17/20	ADD	Research and compile agreements in response to diligence requests for approval and production.	1.80
06/17/20	ADD	Research origination of corrupted file provided in response to diligence requests to produce file to the committee.	0.60
06/17/20	ADD	Review and compile results of third-party entity review for Davis Polk review team.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/17/20	ADD	Review and compile materials in response to diligence request for upload to the data room.	2.90
06/17/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	1.70
06/17/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	1.70
06/18/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	0.80
06/18/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	0.80
06/18/20	ADD	Review and compile materials in response to diligence request for upload to the data room.	2.40
06/19/20	ADD	Compile documentation submitted for project catalyst data room and request necessary approvals.	2.80
06/19/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update and discussion of outstanding items.	1.50
06/19/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	1.50
06/19/20	KG	Load third party production into Relativity. Update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	1.80
06/22/20	KG	Create file listing of new documents loaded and send to A. DePalma (AlixPartners).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/22/20	ADD	Review and index materials provided in response to diligence tax requests.	3.20
06/22/20	ADD	Review and prepare materials submitted in response to Project Catalyst diligence request for upload to the data room.	2.60
06/22/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst data room, diligence status and review of outstanding items.	1.50
06/22/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.50
06/23/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	1.20
06/23/20	ADD	Compile and review Project Catalysts diligence materials to request approval by internal and external counsel for upload to the data room.	2.40
06/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.20
06/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst review of requests for data room access and outstanding diligence requests.	1.30
06/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst review of requests for data room access and outstanding diligence requests.	1.30
06/24/20	KG	Process data for loading. Perform quality control review of processed data. Export and import into Relativity. Image	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/25/20	KG	documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation. Process data for loading. Export and import into Relativity. Load third party production into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation. Generate document listing.	2.20
06/25/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process status discussion and review of submitted information in response to diligence request.	1.60
06/25/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process status discussion and review of submitted information in response to diligence request.	1.60
06/25/20	ADD	Compile and review materials submitted in response to Project Catalyst diligence requests in preparation for upload to the data room.	2.10
06/26/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status and analyses of new inquiries.	1.80
06/26/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation of responses to diligence questions and compilation responses to questionnaires.	2.70
06/26/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation of responses to diligence questions and compilation responses to questionnaires.	2.70
06/26/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status and	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		analyses of new inquiries.	
06/29/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Finance due diligence questions review discussion.	2.10
06/29/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	0.20
06/29/20	ADD	Compile and review responses to Project Catalyst diligence requests and upload files to the data room.	2.70
06/29/20	ADD	Review and recommend redactions in preparation for document production and upload to the data room.	0.30
06/29/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Finance due diligence questions review discussion.	2.10
06/29/20	ADD	Call with A. DePalma and K. McCafferty(AlixPartners); re: Project catalyst due diligence question.	0.20
06/29/20	KG	Process data for loading. Export and import into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	0.80
06/30/20	KG	Process data for loading. Export and import into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	0.40
06/30/20	ADD	Call and analysis with W. DiNicola, D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: finance DD interview questions for third parties.	1.50
06/30/20	ADD	Virtual working session with A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst due diligence status update and compilation of diligence	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		responses.	
06/30/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen (Purdue) re: Operations due diligence questions review.	1.50
06/30/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D .Fogel, W. DiNicola (Purdue) re: Continuation of finance due diligence questions review discussion.	2.00
06/30/20	ADD	Redaction documents submitted in response to diligence requests.	2.20
06/30/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D .Fogel, W. DiNicola (Purdue) re: Continuation of finance due diligence questions review discussion.	2.00
06/30/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen (Purdue) re: Operations due diligence questions review.	1.50
06/30/20	KM	Call and analysis with W. DiNicola, D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: finance DD interview questions for third parties.	1.50
Total			97.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	61.10	515.00	31,466.50
Kristina Galbraith	12.60	645.00	8,127.00
Kevin M McCafferty	24.20	950.00	22,990.00
Total Hours & Fees	97.90		62,583.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
06/01/20	ESK	Attend to disclosure matters.	0.40
06/02/20	ESK	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	ESK	Email J. Fee (AlixPartners) re: disclosure matter.	0.30
06/02/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: disclosure matters.	0.20
06/02/20	GJK	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	LJD	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	JD	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: disclosure matters.	0.20
06/03/20	JD	Correspondence with Davis Polk re: SOFA/SOAL disclosures.	0.40
06/03/20	JD	Call with M. Huebner (Davis Polk), M. Kesselman (Purdue), L. Donahue and J. DelConte (both AlixPartners) re: disclosure matters.	0.50
06/03/20	JD	Review correspondence re: potential disclosures.	0.30
06/03/20	LJD	Prepare for and attend call with M. Huebner (Davis Polk), M. Kesselman (Purdue), L. Donahue and J. DelConte (both AlixPartners) re: disclosure matters.	0.60
06/03/20	LJD	Call L. Donahue, J. DelConte and E. Kardos (all AlixPartners) re: addressing possible disclosure matter.	1.00
06/03/20	ESK	Email to/from T. Antisdell (AlixPartners) re: disclosure report.	0.30
06/03/20	ESK	Call with J. DelConte and E. Kardos (all AlixPartners) re:	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
		various disclosure matters.	
06/03/20	ESK	Call L. Donahue, J. DelConte and E. Kardos (all AlixPartners) re: addressing possible disclosure matter.	1.00
06/03/20	ESK	Email J. Fee (AlixPartners) re: disclosure matter.	0.30
06/03/20	ESK	Prepare disclosure report.	0.30
06/03/20	JD	Call L. Donahue, J. DelConte and E. Kardos (all AlixPartners) re: addressing possible disclosure matter.	1.00
06/03/20	JD	Call with J. DelConte and E. Kardos (all AlixPartners) re: various disclosure matters.	0.60
Total			12.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Elizabeth S Kardos	4.20	710.00	2,982.00
Gabe J Koch	1.20	840.00	1,008.00
Jesse DelConte	4.00	950.00	3,800.00
Lisa Donahue	2.60	1,195.00	3,107.00
Total Hours & Fees	12.00		10,897.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
06/01/20	JD	Begin reviewing draft April fee statement.	1.50
06/01/20	JD	Finalize reviewing and editing draft April fee statement.	2.70
06/01/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.50
06/01/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	1.50
06/02/20	JD	Review final April 2020 professional fees and expenses.	0.30
06/03/20	TB	Prepare eighth monthly fee statement for April 2020 and exhibits.	1.30
06/05/20	JD	Conversation with J. Lowne (Purdue) re: AlixPartners fee statement review.	0.30
06/08/20	JD	Review draft April fee statement and provide comments.	0.40
06/08/20	TB	Update April monthly fee statement and exhibits.	0.40
06/08/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.40
06/09/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.10
06/10/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.70
06/10/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	2.90
06/10/20	MSM	Further preparation of professional fees for May 2020 monthly fee statement.	3.00
06/11/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.30
06/11/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	3.10
06/12/20	MSM	Prepare professional fees for May 2020 monthly fee	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		statement.	
06/12/20	ESK	Review eighth monthly fee statement for the period April 1, 2020 through April 30, 2020.	0.30
06/13/20	ESK	Review email from Davis Polk re: fee examiner request and email response internally re: same.	0.10
06/15/20	ESK	Review eighth monthly fee statement for the period of April 1, 2020 through April 30, 2020.	0.30
06/15/20	JD	Correspondence with accounting re: fee examiner requests.	0.20
06/15/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	2.00
06/16/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	2.70
06/16/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	2.10
06/16/20	JD	Correspondence with Davis Polk and AlixPartners legal re: fee examiner.	0.60
06/16/20	JD	Call with J. DelConte, E. Kardos (both AlixPartners) re: various Purdue matters, including objection to first interim fee application.	0.40
06/16/20	JD	Review initial fee examiner report and back up materials.	1.30
06/16/20	ESK	Review fee examiner report and began to consider responses.	0.50
06/16/20	ESK	Review emails from M. Pera (Davis Polk) re: objection to AlixPartners' first interim fee application.	0.30
06/16/20	ESK	Call with J. DelConte, E. Kardos (both AlixPartners) re: various Purdue matters, including objection to first interim fee application.	0.40
06/16/20	TB	Review professional fees for May 2020 monthly fee	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		statement.	
06/17/20	ESK	Call J. DelConte and B. Fuller (both AlixPartners) to review fee examiner report and prepare response to same.	0.70
06/17/20	ESK	Internal calls re: various case administration matters.	0.50
06/17/20	ESK	Review and provide comments to Fee Examiners' objection to the first interim fee application.	0.80
06/17/20	JD	Draft responses to the fee examiner initial report.	0.90
06/17/20	JD	Call with B. Fuller, E. Kardos and J. DelConte (all AlixPartners) re: fee examiner report.	0.70
06/17/20	BFF	Updates/revisions to draft response to Fee Examiner.	1.90
06/17/20	BFF	Call with E. Kardos and J. DelConte (both AlixPartners) re: preparation of response to Fee Examiner report re: first interim fee application.	0.70
06/17/20	BFF	Prepare draft response to Fee Examiner's report re: first interim fee application.	2.80
06/18/20	BFF	Review air travel receipts in connection with Fee Examiner report re: first interim fee application.	0.60
06/18/20	JD	Review and edit fee examiner response letter. Review underlying data per fee examiner letter.	0.80
06/18/20	ESK	Review and revise Response to Fee Examiner objection to first interim fee application.	1.20
06/19/20	TB	Review professional fees for May 2020 monthly fee statement.	1.00
06/19/20	ESK	Call with E. Kardos, B. Fuller and J. DelConte (both AlixPartners) re: finalizing response to Fee Examiner report re: first interim fee application.	0.60
06/19/20	ESK	Emails to/from L. Donahue (AlixPartners) re: fee examiner response.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
06/19/20	ESK	Review and revise response to fee examiner report.	0.90
06/19/20	JD	Check and finalize fee examiner response. Draft correspondence re: same.	0.70
06/19/20	JD	Call with E. Kardos, B. Filler and J. DelConte (both AlixPartners) re: finalizing response to Fee Examiner report re: first interim fee application.	0.60
06/19/20	JD	Update fee examiner response. Correspondence with E. Kardos and L. Donahue (both AlixPartners) re: same.	0.90
06/19/20	BFF	Call with E. Kardos, B. Filler and J. DelConte (both AlixPartners) re: finalizing response to Fee Examiner report re: first interim fee application.	0.60
06/19/20	BFF	Update response to Fee Examiner report re: first interim fee application.	2.10
06/22/20	BFF	Call with D. Klauder, T. Bielli (both Bielli & Klauder), J. DelConte, E. Kardos and B. Filler (all AlixPartners) re: response to first fee examiner report.	0.50
06/22/20	JD	Call with D. Klauder, T. Bielli (both Bielli & Klauder), J. DelConte, E. Kardos and B. Filler (all AlixPartners) re: response to first fee examiner report.	0.50
06/22/20	JD	Correspondence with E. Kardos and L. Donahue (both AlixPartners) re: fee examiner response and settlement.	0.40
06/22/20	JD	Review fee examiner response letter and fee examiner flagged time entries to prepare for call.	0.40
06/22/20	ESK	Call with D. Klauder, T. Bielli (both Bielli & Klauder), J. DelConte, E. Kardos and B. Filler (all AlixPartners) re: response to first fee examiner report.	0.50
06/22/20	TB	Review professional fees for May 2020 monthly fee statement.	1.60
06/22/20	ESK	Review and respond to emails re: response to Fee	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
06/22/20	ESK	Examiner objection to first interim application.	
06/22/20	ESK	Emails to/from J. DelConte and L. Donahue (both AlixPartners) re: settlement of reduction of fees/expenses.	0.20
06/24/20	JD	Begin reviewing and providing comments to draft May 2020 professional fees and expenses.	2.20
06/24/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	2.50
06/24/20	MSM	Prepare professional fees for June 2020 monthly fee statement.	1.50
06/25/20	JD	Finalize review of draft May fee application.	1.50
Total			79.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Melanie McCabe	39.30	415.00	16,309.50
Brooke F Filler	9.20	445.00	4,094.00
Tammy Brewer	5.50	450.00	2,475.00
Elizabeth S Kardos	8.10	710.00	5,751.00
Jesse DelConte	17.30	950.00	16,435.00
Total Hours & Fees	79.40		45,064.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
06/03/20	JD	Participate telephonically in court hearing on bar date extension.	2.50
06/03/20	RC	Dial into Purdue court hearing re: bar date.	1.70
06/03/20	MFR	Participate in the Court hearing.	2.50
06/23/20	JD	Dial in to Purdue hearing on HRT.	1.00
Total			7.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Mark F Rule	2.50	910.00	2,275.00
Jesse DelConte	3.50	950.00	3,325.00
Richard Collura	1.70	1,090.00	1,853.00
Total Hours & Fees	7.70		7,453.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/01/20	MFR	Review and organization of supporting documents related to Report 1B Intercompany Non-Cash Transfers of Value.	3.10
06/01/20	MFR	Review and analysis of documentation supporting accounts payable analyses.	2.80
06/01/20	MFR	Review and analysis of workpapers supporting Report 1B, Intercompany Non-Cash Transfers of Value.	2.70
06/01/20	SJC	Review of email and files from Haug Partners for 2008 and 2009 Ex-US distributions.	2.50
06/01/20	SJC	Update distribution samples selected by Province new bank statements received from Haug Partners.	3.00
06/01/20	SJC	Continue to update distribution samples selected by Province new bank statements received from Haug Partners.	2.50
06/01/20	RC	Review distribution related documentation gathered in response to requests from the UCC.	1.60
06/01/20	ADD	Review UCC tax requests and compared to responses received from TXP to determine outstanding items.	2.60
06/02/20	JDH	Finalization of 2008 distribution documentation.	2.30
06/02/20	RC	Review additional documentation gathered in response to requests from the UCC's advisors.	0.60
06/02/20	SJC	Update distribution samples selected by Province new bank statements received from Haug Partners.	3.00
06/02/20	SJC	Continue to update distribution samples selected by Province new bank statements received from Haug Partners.	2.00
06/02/20	SJC	Update distributions with new bank statements received from Haug Partners (years 2017, 2015, 2013, 2011, and 2009).	3.00
06/03/20	SJC	Review and redact 2017 board meeting minutes in	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/03/20	SJC	preparation for processing an upload to data room. Review and redact 2016 board meeting minutes in preparation for processing an upload to data room.	3.00
06/03/20	SJC	Review and redact 2015 board meeting minutes in preparation for processing an upload to data room.	3.00
06/03/20	SJC	Review and redact 2014 board meeting minutes in preparation for processing an upload to data room.	1.00
06/03/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.50
06/03/20	RC	Review letter from UCC to the court re: discovery issues with the Sacklers.	0.50
06/04/20	SJC	Review and redact 2018 board meeting minutes in preparation for processing an upload to data room.	3.00
06/04/20	SJC	Review and redact 2017 board meeting minutes in preparation for processing an upload to data room.	1.00
06/05/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.80
06/05/20	RC	Review SAP information related to tax and distribution requests.	0.80
06/07/20	RC	Review and prepare comments related to the summary status of diligence requests and communications with TXP.	0.60
06/07/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: comments re: status of diligence requests.	0.50
06/07/20	RC	Review and update comments related to the status of diligence requests.	0.40
06/07/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: comments re: status of diligence requests.	0.50
06/08/20	RC	Review documentation gathered in response to the UCC's	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		requests for tax and distribution information.	
06/08/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	3.20
06/08/20	SJC	Review and redact Rhodes board materials in preparation for processing an upload to data room.	4.00
06/08/20	SJC	Continue review and redaction of Rhodes board materials in preparation for processing an upload to data room.	4.00
06/09/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/09/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/09/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.40
06/09/20	RC	Review available information gathered in response to additional tax information related requests made by the UCC.	1.40
06/10/20	RC	Review status of information provided by TXP in response to special committee and UCC requests and identify additional follow-up items.	1.30
06/10/20	RC	Review updated TXP diligence request tracker.	0.30
06/10/20	NAS	Research and respond to question from R. Collura (AlixPartners) re: payroll information for admin professionals.	0.40
06/10/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.70
06/10/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to data room.	
06/10/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/11/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/11/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/11/20	RC	Review cash distribution support documentations gathered in response to information requests.	1.30
06/11/20	RC	Outline next steps re: responding to the UCC's requests related to distributions support.	0.40
06/12/20	RC	Review information provided by TXP to the UCC.	0.40
06/12/20	RC	Review summary of distribution support documentation gathered in connection with the UCC's requests.	0.50
06/12/20	RC	Review SAP information related to the UCC's requests for tax information.	0.40
06/12/20	RC	Review cash distribution support documentation in response to requests from the UCC.	0.70
06/12/20	RC	Review communications from FTI and coordinate with Davis Polk re: next steps and related responses.	0.20
06/12/20	RC	Coordinate with team on responding to requests made by FTI related to the cash and non-cash transfers of value reports.	0.30
06/12/20	RC	Review status of compiling cash distribution support documentation related to requests from the UCC.	0.90
06/12/20	SJC	Review and redact Rhodes board materials from the P	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		drive in preparation for processing an upload to data room.	
06/12/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.50
06/14/20	RC	Review summary of work performed in connection with gathering the distribution support documentation.	0.80
06/15/20	RC	Meeting with R. Collura, A. DePalma, S. Canniff (all AlixPartners) re: diligence requests.	1.00
06/15/20	RC	Review documentation related to cash distributions and other diligence requests from the UCC and provide comments to team.	1.30
06/15/20	RC	Review documentation provided by TXP and provide comments related to the diligence tracker.	0.80
06/15/20	SJC	Meeting with R. Collura, A. DePalma, S. Canniff (all AlixPartners) re: diligence requests.	1.00
06/15/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/15/20	SJC	Review and organization of 2017-2008 distributions.	3.00
06/15/20	FOS	Compose email to M. Rule (AlixPartners) re: information requests relating to Report 1B.	1.50
06/16/20	SJC	Review of 2008, 2010, 2012, 2014, and 2016 distributions.	3.00
06/16/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.00
06/16/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to data room.	
06/16/20	RC	Review distribution related information compiled in response to requests from the UCC.	1.20
06/16/20	RC	Review information related to transactions with the IACs.	0.50
06/17/20	RC	Review summary of supporting information related to requests from the UCC.	1.20
06/17/20	RC	Review additional information provided by TXP to the UCC.	0.60
06/17/20	RC	Review and comment on summary of distribution support documentation.	0.80
06/17/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/17/20	SJC	Review of distribution completeness testing.	4.00
06/17/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: Intercompany and non-cash transfers report information requests.	0.20
06/17/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: Intercompany and non-cash transfers report information requests.	0.20
06/18/20	FOS	Review documents received re: supply agreements between debtor companies and IACs.	0.20
06/18/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	2.20
06/18/20	SJC	Working session with S. Canniff, A. DePalma (both AlixPartners) to review TXP/UCC diligence items .	1.00
06/18/20	SJC	Review of distribution completeness testing.	3.50
06/18/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		room.	
06/18/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	1.00
06/18/20	RC	Review and comment on summary of distribution testing analysis.	0.90
06/18/20	RC	Coordinate and schedule calls with FTI re: the cash and non-cash transfers of value reports.	0.10
06/18/20	RC	Review detail transactions related to distribution completeness testing analysis.	0.80
06/18/20	ADD	Working session with S. Canniff, A. DePalma (both AlixPartners) to review TXP/UCC diligence items .	1.00
06/19/20	ADD	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) to review TXP/UCC diligence items and distribution completeness testing.	1.30
06/19/20	ADD	Compile and prepare May MOR for review, signature and upload.	2.90
06/19/20	RC	Review transactions related to distributions completeness testing and provide comments to team.	0.40
06/19/20	RC	Review outline of topics provided by FTI and prepare for upcoming calls re: the transfers of value reports.	0.60
06/19/20	RC	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) to review TXP/UCC diligence items and distribution completeness testing.	1.30
06/19/20	RC	Review summary of distribution completeness testing and provide comments and next steps.	1.10
06/19/20	RC	Review status update provided by TXP's counsel related to tax returns provided.	0.20
06/19/20	RC	Review support documentation related to the non-cash	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		transfers of value report.	
06/19/20	SJC	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) to review TXP/UCC diligence items and distribution completeness testing.	1.30
06/19/20	SJC	Review of distribution completeness testing.	2.00
06/19/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.00
06/19/20	SJC	Continue review of distribution completeness testing.	2.20
06/19/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	1.10
06/22/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	0.80
06/22/20	FOS	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	3.20
06/22/20	FOS	Review SAP data and documents re: preparation for discussion with FTI on report 1B.	3.50
06/22/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: completeness testing for Report 1B.	0.30
06/22/20	FOS	Compose email to R. Collura (AlixPartners) re: completeness testing for Report 1B.	0.20
06/22/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: completeness testing for Report 1B.	0.30
06/22/20	SJC	Review and discussion of distribution completeness testing.	3.00
06/22/20	SJC	Continue review of distribution completeness testing.	2.60
06/22/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/22/20	SJC	Call with R. Collura, S. Canniff (both AlixPartners) re: distributions testing.	0.40
06/22/20	RC	Review additional testing analysis related to transactions with IACs.	1.10
06/22/20	RC	Call with R. Collura, S. Canniff (both AlixPartners) re: distributions testing.	0.40
06/22/20	RC	Draft outline and related responses to questions from FTI re: the cash transfers of value report.	1.30
06/22/20	RC	Review and comment on responses to FTI's questions related to the non-cash transfers of value report.	0.60
06/22/20	RC	Review summary of tax returns provided by TXP.	0.10
06/22/20	RC	Prepare additional responses to questions from FTI and provide draft to Davis Polk.	0.70
06/23/20	RC	Call with R. Collura, M. Rule, F. Silva (all AlixPartners) re: discussion with FTI re: Reports 1A and 1B.	0.80
06/23/20	RC	Review various testing analyses related to the non-cash transfers of value report.	0.30
06/23/20	RC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	RC	Call with R. Collura and J. DelConte (both AlixPartners) re: case status update prior to diligence calls with FTI on the investigative reports.	0.30
06/23/20	RC	Update outline of responses to questions received from FTI re: the cash transfers and intercompany non-cash transfers of value report.	0.70
06/23/20	SJC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	SJC	Continue review and integration of Province samples into distribution sample population.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/23/20	SJC	Review and integration of Province samples into distribution sample population.	2.20
06/23/20	SJC	Review of distribution completeness testing.	2.00
06/23/20	MFR	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	MFR	Prepare for and participate in call with R. Collura, M. Rule, F. Silva (all AlixPartners) re: discussion with FTI re: Reports 1A and 1B.	1.20
06/23/20	FOS	Call with R. Collura, M. Rule, F. Silva (all AlixPartners) re: discussion with FTI re: Reports 1A and 1B.	0.80
06/23/20	FOS	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	1.50
06/23/20	ADD	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	JD	Call with R. Collura and J. DelConte (both AlixPartners) re: case status update prior to diligence calls with FTI on the investigative reports.	0.30
06/24/20	ADD	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10
06/24/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: cash transfers of value report and status of diligence requests.	0.20
06/24/20	MFR	Prepare for call with FTI re: Report 1B (Intercompany/Non-Cash Transfers of Value Report).	2.00
06/24/20	FOS	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	
06/24/20	FOS	Conference call with R. Collura, M. Rule, and F. Silva (all AlixPartners) re: FTI requests on Reports 1A and 1B.	0.70
06/24/20	MFR	Prepare for and participate in call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.50
06/24/20	MFR	Conference call with R. Collura, M. Rule, and F. Silva (all AlixPartners) re: FTI requests on Reports 1A and 1B.	0.70
06/24/20	SJC	Review and integration of Province samples into distribution sample population.	3.00
06/24/20	SJC	Continue review and integration of Province samples into distribution sample population.	2.90
06/24/20	SJC	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10
06/24/20	RC	Review cash transfers of value report and prepare for call with FTI.	1.20
06/24/20	RC	Conference call with R. Collura, M. Rule, and F. Silva (all AlixPartners) re: FTI requests on Reports 1A and 1B.	0.70
06/24/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: cash transfers of value report and status of diligence requests.	0.20
06/24/20	RC	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/25/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: call with FTI re: the intercompany and non-cash transfers of value report.	0.50
06/25/20	RC	Provide update to Davis Polk re: call with FTI re: the special committee reports.	0.10
06/25/20	RC	Review tax information provided byTXP's counsel and identify follow-up work to perform.	0.30
06/25/20	RC	Review intercompany and non-cash transfers of value report in Prepare for call with FTI.	0.60
06/25/20	RC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/25/20	SJC	Continue review and integration of Province samples into distribution sample population.	3.40
06/25/20	SJC	Review and integration of Province samples into distribution sample population.	3.50
06/25/20	SJC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/25/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: call with FTI re: the intercompany and non-cash transfers of value report.	0.50
06/25/20	MFR	Prepare for and participate in call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Value Report Discussion.	
06/25/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	1.20
06/25/20	FOS	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/25/20	ADD	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/26/20	ADD	Working session with A. DePalma, S. Canniff (both AlixPartners) to review PPLP distributions and tax returns.	0.80
06/26/20	SJC	Pulling support for 2017 and 2016 tax distributions for data room.	3.50
06/26/20	SJC	Analysis of distributions contained within tax filings.	3.50
06/26/20	SJC	Working session with A. DePalma, S. Canniff (both AlixPartners) to review PPLP distributions and tax returns.	0.80
06/26/20	RC	Review support documentation compiled for tax distributions and provide comments to team.	0.80
06/29/20	RC	Review support documentation for tax distributions and provide comments to team.	0.70
06/29/20	SJC	Review of 2016 tax distributions for upload to data room.	0.60
06/29/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.00
06/29/20	SJC	Continue to review and redact Rhodes board materials	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		from the P drive in preparation for processing an upload to data room.	
06/29/20	SJC	Review and integration of Province samples into distribution sample population.	3.50
06/30/20	SJC	Adding distribution support to 2016 tax distribution samples.	1.00
06/30/20	SJC	Review 2017 tax distributions.	2.00
06/30/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	1.60
06/30/20	SJC	Review and analysis of all distributions with supporting documentation.	1.50
06/30/20	SJC	Review of 2016 tax distributions.	2.00
06/30/20	SJC	Call with S. Canniff, R. Collura (both AlixPartners) re: tax distribution support documentation.	0.40
06/30/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: tax distribution support documentation and next steps.	0.20
06/30/20	RC	Review tax distribution support gathered in response to requests from the UCC and provide comments to team.	1.30
06/30/20	RC	Call with S. Canniff, R. Collura (both AlixPartners) re: tax distribution support documentation.	0.40
06/30/20	RC	Review support documentation available in the SAP system related to tax distribution requests from the UCC.	1.20
06/30/20	ADD	Review tax distribution support compiled in preparation for upload to the data room.	2.20
06/30/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: tax distribution support documentation and next steps.	0.20
Total			278.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	14.70	515.00	7,570.50
Nate A Simon	0.40	515.00	206.00
Fernando O Silva	13.60	645.00	8,772.00
Sam J Canniff	162.90	645.00	105,070.50
Jon D Hecht	2.30	690.00	1,587.00
Mark F Rule	37.70	910.00	34,307.00
Jesse DelConte	0.30	950.00	285.00
Richard Collura	46.30	1,090.00	50,467.00
Total Hours & Fees	278.20		208,265.00

Exhibit B

AlixPartners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2
Re: Expense
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
02/04/20	Conference Calls Vendor: Vodafone Fernando Silva	1.73
02/11/20	Conference Calls Vendor: Vodafone Fernando Silva	2.08
02/13/20	Conference Calls Vendor: Vodafone Fernando Silva	2.13
02/18/20	Conference Calls Vendor: Vodafone Jesse Delconte	7.37
02/19/20	Conference Calls Vendor: Vodafone Ryan Sublett	0.12
02/19/20	Conference Calls Vendor: Vodafone Fernando Silva	2.81
02/20/20	Conference Calls Vendor: Vodafone Jesse Delconte	21.12
02/20/20	Conference Calls Vendor: Vodafone Fernando Silva	2.30
02/21/20	Conference Calls Vendor: VODAFONE Nate Simon	2.82
02/21/20	Conference Calls Vendor: VODAFONE Nate Simon	14.88
02/24/20	Conference Calls Vendor: VODAFONE Nate Simon	1.36
03/05/20	Conference Calls Vendor: Vodafone Nate Simon	2.52
03/24/20	Conference Calls Vendor: Vodafone Nate Simon	4.82
03/26/20	Conference Calls Vendor: Vodafone Nate Simon	11.06
03/31/20	Conference Calls Vendor: Vodafone Nate Simon	8.07
06/16/20	Copy Costs (Outside Source) Nathaniel Simon Print Draft Mundi Report For Review	95.70
06/30/20	Client Research PACER Service Center / Pacer: court records access/downloads	12.90
Total Disbursements		193.79

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126029-2
Re: Expense
Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Other	193.79
Total Disbursements	193.79